View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Nov. 04, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Trading Symbol	ACHC
Entity Registrant Name	Acadia Healthcare Company, Inc.
Entity Central Index Key	0001520697
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		71,688,455

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 50,762	$ 94,040
Accounts receivable, net of allowance for doubtful accounts of $27,378 and $22,449, respectively	214,883	118,378
Deferred tax assets	37,291	20,155
Other current assets	75,335	41,570
Total current assets	378,271	274,143
Property and equipment, net	1,624,166	1,069,700
Goodwill	1,981,140	802,986
Intangible assets, net	58,976	21,636
Deferred tax assets - noncurrent	33,278	13,141
Other assets	69,408	41,984
Total assets	4,145,239	2,223,590
Current liabilities:
Current portion of long-term debt	41,996	26,965
Accounts payable	78,384	48,696
Accrued salaries and benefits	87,110	59,317
Other accrued liabilities	56,962	30,956
Total current liabilities	264,452	165,934
Long-term debt	2,092,317	1,069,305
Deferred tax liabilities - noncurrent	22,210	63,880
Other liabilities	87,008	43,506
Total liabilities	2,465,987	1,342,625
Redeemable noncontrolling interests	8,700
Equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued
Common stock, $0.01 par value; 90,000,000 shares authorized; 70,716,128 and 59,211,859 issued and outstanding as of September 30, 2015 and December 31, 2014, respectively	707	592
Additional paid-in capital	1,574,708	847,301
Accumulated other comprehensive loss	(84,293)	(68,370)
Retained earnings	179,430	101,442
Total equity	1,670,552	880,965
Total liabilities and equity	$ 4,145,239	$ 2,223,590

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Receivable, allowance for doubtful accounts	$ 27,378	$ 22,449
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	90,000,000	90,000,000
Common stock, shares issued	70,716,128	59,211,859
Common stock, shares outstanding	70,716,128	59,211,859

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Revenue before provision for doubtful accounts	$ 488,746	$ 303,001	$ 1,324,702	$ 729,784
Provision for doubtful accounts	(9,016)	(8,522)	(25,529)	(20,084)
Revenue	479,730	294,479	1,299,173	709,700
Salaries, wages and benefits (including equity-based compensation expense of $5,327, $2,805, $14,576 and $6,975, respectively)	258,410	168,632	707,583	408,680
Professional fees	30,759	14,878	83,215	36,151
Supplies	21,634	14,062	58,430	34,722
Rents and leases	8,542	3,214	22,639	8,872
Other operating expenses	57,244	31,432	148,899	79,188
Depreciation and amortization	16,890	10,325	44,920	21,696
Interest expense, net	27,737	14,068	77,932	33,505
Debt extinguishment costs	9,979		9,979
Loss (gain) on foreign currency derivatives	1,018	(1,527)	1,926	(15,262)
Transaction-related expenses	5,842	6,239	31,415	10,834
Total expenses	438,055	261,323	1,186,938	618,386
Income from continuing operations before income taxes	41,675	33,156	112,235	91,314
Provision for income taxes	12,669	7,703	34,794	30,383
Income (loss) from continuing operations	29,006	25,453	77,441	60,931
Income (loss) from discontinued operations, net of income taxes	80	(51)	83	(20)
Net income	29,086	25,402	77,524	60,911
Net loss attributable to noncontrolling interests	464		464
Net income attributable to Acadia Healthcare Company, Inc.	$ 29,550	$ 25,402	$ 77,988	$ 60,911
Basic earnings attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations	$ 0.42	$ 0.43	$ 1.16	$ 1.14
Income (loss) from discontinued operations	0	0	0	0
Net income	0.42	0.43	1.16	1.14
Diluted earnings attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations	0.42	0.43	1.15	1.13
Income (loss) from discontinued operations	0	0	0	0
Net income	$ 0.42	$ 0.43	$ 1.15	$ 1.13
Weighted-average shares outstanding:
Basic	70,664	59,175	67,194	53,670
Diluted	71,110	59,409	67,539	53,922

Condensed Consolidated Statements of Income (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Equity-based compensation expense	$ 5,327	$ 2,805	$ 14,576	$ 6,975

Condensed Consolidated Statements of Comprehensive (Loss) Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]
Net income	$ 29,086	$ 25,402	$ 77,524	$ 60,911
Other comprehensive income:
Foreign currency translation loss	(32,707)	(36,857)	(15,923)	(36,857)
Other comprehensive income	(32,707)	(36,857)	(15,923)	(36,857)
Comprehensive (loss) income	(3,621)	(11,455)	61,601	24,054
Comprehensive loss income attributable to noncontrolling interests	464		464
Comprehensive (loss) income attributable to Acadia Healthcare Company. Inc.	$ (3,157)	$ (11,455)	$ 62,065	$ 24,054

Condensed Consolidated Statement of Equity (Unaudited) - 9 months ended Sep. 30, 2015 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2014	$ 880,965	$ 592	$ 847,301	$ (68,370)	$ 101,442
Balance, shares at Dec. 31, 2014	59,211,859	59,212,000
Common stock issued under stock incentive plans	$ 1,619	$ 4	1,615
Common stock issued under stock incentive plans, shares	204,867	354,000
Common stock withheld for minimum statutory taxes	$ (9,201)		(9,201)
Equity-based compensation expense	14,576		14,576
Excess tax benefit from equity awards	8,020		8,020
Issuance of common stock, net	711,571	$ 111	711,460
Issuance of common stock, net, shares		11,150,000
Other comprehensive loss	(15,923)			(15,923)
Other	937		937
Net income	77,988				77,988
Balance at Sep. 30, 2015	$ 1,670,552	$ 707	$ 1,574,708	$ (84,293)	$ 179,430
Balance, shares at Sep. 30, 2015	70,716,128	70,716,000

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating activities:
Net income	$ 77,524	$ 60,911
Adjustments to reconcile net income to net cash provided by continuing operating activities:
Depreciation and amortization	44,920	21,696
Amortization of debt issuance costs	5,017	2,229
Equity-based compensation expense	14,576	6,975
Deferred income tax expense	28,925	4,645
(Income) loss from discontinued operations, net of taxes	(83)	20
Debt extinguishment costs	9,979
Loss (gain) on foreign currency derivatives	1,926	(15,262)
Other	1,122	163
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net	(28,905)	(25,395)
Other current assets	(12,201)	1,322
Other assets	(4,879)	(2,086)
Accounts payable and other accrued liabilities	(8,316)	1,078
Accrued salaries and benefits	8,888	8,972
Other liabilities	5,071	3,805
Net cash (used in) provided by continuing operating activities	143,564	69,073
Net cash provided by (used in) discontinued operating activities	(1,479)	(27)
Net cash provided by operating activities	142,085	69,046
Investing activities:
Cash paid for acquisitions, net of cash acquired	(391,216)	(722,797)
Cash paid for capital expenditures	(200,841)	(70,680)
Cash paid for real estate acquisitions	(21,976)	(22,247)
Settlement of foreign currency derivatives	(1,926)	15,262
Other	(887)	(733)
Net cash used in investing activities	(616,846)	(801,195)
Financing activities:
Borrowings on long-term debt	1,150,000	307,500
Borrowings on revolving credit facility	310,000	230,500
Principal payments revolving credit facility	(310,000)	(120,000)
Principal payments on long-term debt	(23,813)	(5,625)
Repayment of assumed CRC debt	(904,467)
Repayment of senior notes	(88,331)
Payment of debt issuance costs	(25,584)	(10,909)
Payment of premium on senior notes	(6,890)
Issuance of common stock, net	331,360	374,431
Common stock withheld for minimum statutory taxes, net	(7,582)	(3,477)
Excess tax benefit from equity awards	8,020	3,779
Cash paid for contingent consideration		(5,000)
Other	(374)
Net cash provided by (used in) financing activities	432,339	771,199
Effect of exchange rate changes on cash	(856)	(1,440)
Net (decrease) increase in cash and cash equivalents	(43,278)	37,610
Cash and cash equivalents at beginning of the period	94,040	4,569
Cash and cash equivalents at end of the period	50,762	42,179
Effect of acquisitions:
Assets acquired, excluding cash	1,793,139	802,767
Liabilities assumed	(1,012,549)	(78,003)
Issuance of common stock in connection with acquisition	(380,210)
Redeemable noncontrolling interests resulting from an acquisition	(9,164)
Contingent consideration issued in connection with acquisition		(1,467)
Prior year deposits paid for acquisitions		(500)
Cash paid for acquisitions, net of cash acquired	$ 391,216	$ 722,797

Description of Business and Basis of Presentation

9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Description of Business and Basis of Presentation

1.	Description of Business and Basis of Presentation

Description of Business

Acadia Healthcare Company, Inc. (the “Company”) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States, the United Kingdom and Puerto Rico. At September 30, 2015, the Company operated 233 behavioral healthcare facilities with over 9,600 beds in 37 states, the United Kingdom and Puerto Rico.

Basis of Presentation

The business of the Company is conducted through limited liability companies, partnerships and C-corporations. The Company’s consolidated financial statements include the accounts of the Company and all subsidiaries controlled by the Company through its’ direct or indirect ownership of majority interests and exclusive rights granted to the Company as the controlling member of an entity. All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation of our financial position and results of operations have been included. The Company’s fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The condensed consolidated balance sheet at December 31, 2014 has been derived from the audited financial statements as of that date. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the fiscal year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 27, 2015. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Certain reclassifications have been made to prior years to conform to the current year presentation.

Earnings Per Share

9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Earnings Per Share

2.	Earnings Per Share

Basic and diluted earnings per share are calculated in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 260, “Earnings Per Share,” based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities have a dilutive effect on earnings per share.

The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2015 and 2014 (in thousands, except per share amounts):


	Three Months Ended September 30,					Nine Months Ended September 30,
	2015		2014			2015		2014
Numerator:
Basic and diluted earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations	$	29,470	$	25,453		$	77,905	$	60,931
Income (loss) from discontinued operations		80		(51	)		83		(20	)

Net income	$	29,550	$	25,402		$	77,988	$	60,911

Denominator:
Weighted average shares outstanding for basic earnings per share		70,664		59,175			67,194		53,670
Effect of dilutive instruments		446		234			345		252

Shares used in computing diluted earnings per common share		71,110		59,409			67,539		53,922

Basic earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations	$	0.42	$	0.43		$	1.16	$	1.14
Income (loss) from discontinued operations		—		—			—		—

Net income	$	0.42	$	0.43		$	1.16	$	1.14

Diluted earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations	$	0.42	$	0.43		$	1.15	$	1.13
Income (loss) from discontinued operations		—		—			—		—

Net income	$	0.42	$	0.43		$	1.15	$	1.13

Approximately 0.3 million and 0.5 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for the three months ended September 30, 2015 and 2014, respectively, because their effect would have been anti-dilutive. Approximately 0.9 million and 0.7 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for the nine months ended September 30, 2015 and 2014, respectively, because their effect would have been anti-dilutive.

Acquisitions

9 Months Ended

Sep. 30, 2015

Business Combinations [Abstract]

Acquisitions

3.	Acquisitions

UK Acquisitions

On September 1, 2015, the Company completed the acquisitions of (i) three facilities from The Danshell Group (“Danshell”) for approximately $59.8 million, (ii) two facilities from Health and Social Care Partnerships (“H&SCP”) for approximately $26.2 million and (iii) Manor Hall for approximately $14.0 million. The inpatient psychiatric facilities acquired from Danshell have an aggregate of 73 beds and are located in England. The inpatient psychiatric facilities acquired from H&SCP have an aggregate of 50 beds and are located in England. Manor Hall has 26 beds and is located in England.

On July 1, 2015, the Company completed the acquisition of The Manor Clinic, a substance abuse facility with 15 beds located in England, for cash consideration of approximately $5.9 million.

On June 1, 2015, the Company completed the acquisitions of (i) one facility from Choice Lifestyles (“Choice”) for approximately $25.9 million and (ii) 15 facilities from Care UK Limited (“Care UK”) for approximately $88.2 million. The inpatient psychiatric facility acquired from Choice has 42 beds and is located in England. The inpatient psychiatric facilities acquired from Care UK have an aggregate of 299 beds and are located in England.

On April 1, 2015, the Company completed the acquisitions of (i) two facilities from Choice for approximately $37.5 million, (ii) Pastoral Care Group (“Pastoral”) for approximately $34.2 million and (iii) Mildmay Oaks f/k/a Vista Independent Hospital (“Mildmay Oaks”) for approximately $14.9 million. The two inpatient psychiatric facilities acquired from Choice have an aggregate of 48 beds and are located in England. Pastoral operates two inpatient psychiatric facilities with an aggregate of 65 beds located in Wales. Mildmay Oaks is an inpatient psychiatric facility with 67 beds located in England.

Southcoast

On August 31, 2015, the Company completed the acquisition of a controlling interest in Southcoast Behavioral (“Southcoast”), an inpatient psychiatric facility located in Fairhaven, Massachusetts. The Company owns 75% of the equity interests in the facility. The value of the 25% noncontrolling interest approximates $9.2 million. The Company considered an income approach and other valuation methodologies to value the noncontrolling interests. The Company consolidates the operations of the facility based on its 75% equity ownership and its management of the entity. The noncontrolling interests are reflected as redeemable noncontrolling interests on the accompanying condensed consolidated balance sheet based on a put right that could require the Company to purchase the noncontrolling interests upon the occurrence of a change in control.

Belmont

On July 1, 2015, the Company completed the acquisition of the assets of Belmont Behavioral Health (“Belmont”), an inpatient psychiatric facility with 147 beds located in Philadelphia, Pennsylvania for cash consideration of approximately $40.0 million which consists of $35.0 million base purchase price and an estimated working capital settlement of $5.0 million.

QAM

On March 1, 2015, the Company acquired the stock of Quality Addiction Management, Inc. (“QAM”) for total consideration of approximately $54.6 million. QAM operates seven comprehensive treatment centers located in Wisconsin.

CRC

On February 11, 2015, the Company completed its acquisition of CRC Health Group, Inc. (“CRC”) for total consideration of approximately $1.3 billion. As consideration for the acquisition, the Company issued 5,975,326 shares of its common stock to certain holders of CRC common stock and repaid CRC’s outstanding indebtedness of $904.5 million. CRC is a leading provider of treatment services related to substance abuse and other addiction and behavioral disorders. At the acquisition date, CRC operated 35 inpatient facilities with over 2,400 beds and 81 comprehensive treatment centers located in 30 states.

2014 Acquisitions

On December 1, 2014, the Company acquired the assets of Croxton Warwick Lodge (“Croxton”), an inpatient psychiatric facility with 24 beds located in England, for cash consideration of $15.6 million. On December 31, 2014, the Company completed the acquisition of Skyway House (“Skyway”), a substance abuse facility with 28 beds located in Chico, California, for cash consideration of $0.3 million. On September 3, 2014, the Company completed the acquisition of McCallum Place (“McCallum”), an eating disorder treatment facility with 85 beds offering residential, partial hospitalization and intensive outpatient treatment programs located in St. Louis, Missouri, and Austin, Texas, for total consideration of $37.4 million. On July 1, 2014, the Company acquired Partnerships in Care for cash consideration of $661.7 million, which was net of cash acquired of $12.0 million and the gain on settlement of foreign currency derivatives of $15.3 million. At the acquisition date, Partnerships in Care was the second largest independent provider of inpatient behavioral healthcare services in the United Kingdom, operating 23 inpatient behavioral healthcare facilities with over 1,200 beds. On January 1, 2014, the Company acquired the assets of Pacific Grove Hospital (“Pacific Grove”), an inpatient psychiatric facility with 68 beds located in Riverside, California, for cash consideration of $10.5 million.

Summary of Acquisitions

The Company selectively seeks opportunities to expand and diversify its base of operations by acquiring additional facilities. Approximately $174.5 million of the goodwill associated with domestic acquisitions completed in 2015 and 2014 is deductible for federal income tax purposes. The fair values assigned to certain assets and liabilities assumed by the Company have been estimated on a preliminary basis and are subject to change as new facts and circumstances emerge that were present at the date of acquisition. Specifically, the Company is further assessing the valuation of certain real property and intangible assets and certain tax matters as well as certain receivables and assumed liabilities of Danshell, H&SCP, Manor Hall, The Manor Clinic, Belmont, Choice, Care UK, Pastoral, Mildmay Oaks, QAM and CRC.

The preliminary fair values of assets acquired and liabilities assumed, at the corresponding acquisition dates, during the nine months ended September 30, 2015 in connection with the 2015 acquisitions were as follows (in thousands):


	CRC		Other		Total
Cash	$	19,600	$	5,141	$	24,741
Accounts receivable		47,095		20,917		68,012
Prepaid expenses and other current assets		26,448		1,207		27,655
Property and equipment		137,243		241,629		378,872
Goodwill		1,052,049		152,494		1,204,543
Intangible assets		37,000		204		37,204
Deferred tax assets – noncurrent		70,375		—		70,375
Other assets		6,478		—		6,478

Total assets acquired		1,396,288		421,592		1,817,880
Accounts payable		4,752		1,960		6,712
Accrued salaries and benefits		14,889		2,658		17,547
Other accrued expenses		38,638		3,848		42,486
Deferred tax liabilities – noncurrent		—		1,357		1,357
Long-term debt		904,467		2		904,469
Other liabilities		39,967		11		39,978

Total liabilities assumed		1,002,713		9,836		1,012,549

Redeemable noncontrolling interests		—		9,164		9,164

Net assets acquired	$	393,575	$	402,592	$	796,167

The preliminary fair values of assets acquired and liabilities assumed, at the corresponding acquisition dates, during the year ended December 31, 2014 in connection with the 2014 acquisitions were as follows (in thousands):


	Partnerships in Care		Other		Total
Cash	$	11,674	$	—	$	11,674
Accounts receivable		7,684		1,849		9,533
Prepaid expenses and other current assets		8,828		169		8,997
Property and equipment		610,477		27,203		637,680
Goodwill		92,959		32,232		125,191
Intangible assets		651		204		855
Other assets		7,037		3,240		10,277

Total assets acquired		739,310		64,897		804,207
Accounts payable		3,958		93		4,051
Accrued salaries and benefits		10,422		—		10,422
Other accrued expenses		7,166		1,014		8,180
Deferred tax liabilities – noncurrent		21,509		—		21,509
Other liabilities		7,704		—		7,704

Total liabilities assumed		50,759		1,107		51,866

Net assets acquired	$	688,551	$	63,790	$	752,341

Other

The qualitative factors comprising the goodwill acquired in the Pacific Grove, Partnerships in Care, McCallum, Croxton, Skyway, CRC, QAM, Choice, Pastoral, Mildmay Oaks, Care UK, The Manor Clinic, Belmont, Southcoast, Danshell, H&SCP and Manor Hall acquisitions (collectively the “2014 and 2015 Acquisitions”) include efficiencies derived through synergies expected by the elimination of certain redundant corporate functions and expenses, the ability to leverage call center referrals to a broader provider base, coordination of services provided across the combined network of facilities, achievement of operating efficiencies by benchmarking performance, and applying best practices throughout the combined companies.

Transaction-related expenses comprised the following costs for the three and nine months ended September 30, 2015 and 2014 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Advisory and financing commitment fees	$	—	$	—	$	10,337	$	—
Legal, accounting and other costs		5,261		5,935		14,315		10,071
Severance and contract termination costs		581		304		6,763		763

	$	5,842	$	6,239	$	31,415	$	10,834

Pro Forma Information

The condensed consolidated statements of income for the three and nine months ended September 30, 2015 include revenue of $250.0 million and $619.7 million, respectively, and income from continuing operations before income taxes of $37.5 million and $95.2 million, respectively, related to the 2014 and 2015 Acquisitions. The condensed consolidated statements of income for the three and nine months ended September 30, 2014 include revenue of $78.8 million and $81.8 million, respectively, and income from continuing operations before income taxes of $6.2 million and $6.1 million, respectively, related to acquisitions completed in 2014.

The following table provides certain pro forma financial information for the Company as if the 2014 and 2015 Acquisitions occurred as of January 1, 2014 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Revenue	$	485,680	$	480,695	$	1,424,587	$	1,321,938

Income from continuing operations, before income taxes	$	43,101	$	47,340	$	87,511	$	91,591

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Other Intangible Assets

9 Months Ended

Sep. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Other Intangible Assets

4.	Other Intangible Assets

Other identifiable intangible assets and related accumulated amortization consisted of the following as of September 30, 2015 and December 31, 2014 (in thousands):


	Gross Carrying Amount				Accumulated Amortization
	September 30, 2015		December 31, 2014		September 30, 2015			December 31, 2014
Intangible assets subject to amortization:
Contract intangible assets	$	2,100	$	2,100	$	(1,645	)	$	(1,330	)
Non-compete agreements		1,247		1,247		(1,226	)		(1,155	)

		3,347		3,347		(2,871	)		(2,485	)

Intangible assets not subject to amortization:
Licenses and accreditations		10,779		9,184		—			—
Trade names		37,800		3,000		—			—
Certificates of need		9,921		8,590		—			—

		58,500		20,774		—			—

Total	$	61,847	$	24,121	$	(2,871	)	$	(2,485	)

In connection with the CRC acquisition, the Company acquired license and accreditation intangible assets with a fair value of $1.1 million, trade name intangible assets with a fair value of $34.8 million and certificate of need intangible assets with a fair value of $1.1 million.

Amortization expense related to definite-lived intangible assets was $0.1 million for both the three months ended September 30, 2015 and 2014, and $0.4 million for both the nine months ended September 30, 2015 and 2014. Estimated amortization expense for the years ending December 31, 2015, 2016, 2017, 2018 and 2019 is $0.5 million, $0.4 million, $0, $0 and $0, respectively. The Company’s licenses and accreditations, trade names and certificate of need intangible assets have indefinite lives and are, therefore, not subject to amortization.

Property and Equipment

9 Months Ended

Sep. 30, 2015

Text Block [Abstract]

Property and Equipment

5.	Property and Equipment

Property and equipment consists of the following as of September 30, 2015 and December 31, 2014 (in thousands):


	September 30, 2015			December 31, 2014
Land	$	209,297		$	132,406
Building and improvements		1,229,551			858,055
Equipment		127,275			73,584
Construction in progress		159,336			66,268

		1,725,459			1,130,313
Less accumulated depreciation		(101,293	)		(60,613	)

Property and equipment, net	$	1,624,166		$	1,069,700

Long-Term Debt

9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Long-Term Debt

6.	Long-Term Debt

Long-term debt consisted of the following (in thousands):


	September 30, 2015			December 31, 2014
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loans (net of discount of $1,501 and $1,924, respectively)	$	505,937		$	525,576
Senior Secured Term B Loans (net of discount of $2,295)		493,955			—
Senior Secured Revolving Line of Credit		—			—
12.875% Senior Notes due 2018 (net of discount of $68 and $1,080, respectively)		9,101			96,420
6.125% Senior Notes due 2021		150,000			150,000
5.125% Senior Notes due 2022		300,000			300,000
5.625% Senior Notes due 2023 (net of premium of $1,375)		651,375			—
9.0% and 9.5% Revenue Bonds (net of premium of $1,320 and $1,649, respectively)		23,945			24,274

		2,134,313			1,096,270
Less: current portion		(41,996	)		(26,965	)

Long-term debt	$	2,092,317		$	1,069,305

Amended and Restated Senior Credit Facility

The Company entered into a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, the Company entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) which amended and restated the Senior Secured Credit Facility (“Amended and Restated Senior Credit Facility”).

On February 13, 2014, the Company entered into a Fourth Amendment (the “Fourth Amendment”) to the Amended and Restated Credit Agreement, to increase the size of the Amended and Restated Senior Credit Facility and extend the maturity date thereof, which resulted in the Company having a revolving line of credit of up to $300.0 million and term loans of $300.0 million. The Fourth Amendment also reduced the interest rates applicable to the Amended and Restated Senior Credit Facility and provided increased flexibility to the Company in terms of the financial and other restrictive covenants. The Fourth Amendment also provides for a $150.0 million incremental credit facility, with the potential for unlimited additional incremental amounts, provided the Company meets certain financial ratios, in each case subject to customary conditions precedent to borrowing.

On June 16, 2014, the Company entered into a Fifth Amendment (the “Fifth Amendment”) to the Amended and Restated Credit Agreement. The Fifth Amendment specifically permitted the Company’s acquisition of Partnerships in Care, gave the Company the ability to incur a tranche of term loan B debt in the future through its incremental credit facility, and modified certain of the restrictive covenants on miscellaneous investments and incurrence of miscellaneous liens. Finally, the Fifth Amendment provided increased flexibility to the Company in terms of its financial covenants.

On December 15, 2014, the Company entered into a Sixth Amendment (the “Sixth Amendment”) to our Amended and Restated Credit Agreement. Pursuant to the Sixth Amendment, the Company incurred $235.0 million of additional term loans. A portion of the additional term loan advance was used to prepay its outstanding revolving loans, and a portion of the additional term loan advance is being held as cash on the consolidated balance sheet. The Sixth Amendment also specifically permitted the acquisition of CRC. In connection with the acquisition of CRC, the Sixth Amendment (i) imposed a temporary reserve on the Company’s revolving credit facility in the amount of $110.0 million in order to preserve such reserved amounts for later borrowings to partially fund the consideration for the acquisition of CRC (subject to limited conditionality provisions) (the reserve is no longer in effect due to the acquisition of CRC), (ii) permitted the incurrence of an additional incremental term loan facility under the Amended and Restated Credit Agreement partially to fund the consideration for the acquisition of CRC (subject to limited conditionality provisions) and (iii) permitted the issuance of additional senior unsecured indebtedness or senior unsecured bridge indebtedness partially to fund the consideration for the acquisition of CRC.

The Company’s baskets for permitted investments were also increased to provide increased flexibility for the Company to invest in non-wholly owned subsidiaries, joint ventures and foreign subsidiaries. The Company may now invest in non-wholly owned subsidiaries and joint ventures up to 7.5% of the Company’s and its subsidiaries’ total assets in any fiscal year, and up to 10% of the Company’s and its subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The Company may also invest in foreign subsidiaries that are not loan parties up to 10% of the Company’s and its subsidiaries’ total assets in any fiscal year, and up to 15% of the Company’s and its subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The foregoing permitted investments are subject to an aggregate cap of 20% of the Company’s and its subsidiaries’ total assets in any fiscal year.

The Sixth Amendment also permits the Company, subject to certain consents, to add one or more foreign borrowers and/or request revolving loans and letters of credit in foreign currencies.

On February 6, 2015, the Company entered into a Seventh Amendment (the “Seventh Amendment”) to our Amended and Restated Credit Agreement. The Seventh Amendment added Citibank, N.A. as an “L/C Issuer” under the Amended and Restated Credit Agreement in order to permit the rollover of CRC’s existing letters of credit into the Amended and Restated Credit Agreement and increased both the Company’s Letter of Credit Sublimit and Swing Line Sublimit to $20.0 million.

On February 11, 2015, the Company entered into a First Incremental Facility Amendment (the “First Incremental Amendment”) to our Amended and Restated Credit Agreement. The First Incremental Amendment activated a new $500.0 million incremental Term Loan B facility (the “TLB Facility”) that was added to our Amended and Restated Senior Credit Facility, subject to limited conditionality provisions. Borrowings under the TLB Facility were used to fund a portion of the purchase price for the acquisition of CRC.

On April 22, 2015, the Company entered into an Eighth Amendment (the “Eighth Amendment”) to our Amended and Restated Credit Agreement. The Eighth Amendment changed the definition of “Change of Control” in part to remove a provision whose purpose was, when calculating whether a majority of incumbent directors have approved new directors, that any incumbent director that became a director as a result of a threatened or actual proxy contest was not counted in such calculation.

The Company had $293.7 million of availability under the revolving line of credit as of September 30, 2015. Borrowings under the revolving line of credit are subject to customary conditions precedent to borrowing. The Amended and Restated Credit Agreement requires quarterly term loan principal repayments of our outstanding term loan A loans (“TLA Facility”) of $6.7 million for September 30, 2015 to December 31, 2015, $10.0 million for March 31, 2016 to December 31, 2016, $13.4 million for September 30, 2017 to December 31, 2017, and $16.7 million for March 31, 2018 to December 31, 2018, with the remaining principal balance of the TLA Facility due on the maturity date of February 13, 2019. On December 15, 2014, prior to the execution of the Sixth Amendment, the Company prepaid the December 31, 2014 quarterly term loan principal payment of $1.9 million. The Company is required to repay the TLB Facility in equal quarterly installments of $1.3 million on the last business day of each March, June, September and December, with the outstanding principal balance of the TLB Facility due on February 11, 2022.

Borrowings under the Amended and Restated Senior Credit Facility are guaranteed by each of the Company’s wholly-owned domestic subsidiaries (other than certain excluded subsidiaries) and are secured by a lien on substantially all of the assets of the Company and such subsidiaries. Borrowings with respect to the TLA Facility and the Company’s revolving credit facility (collectively, “Pro Rata Facilities”) under the Amended and Restated Credit Agreement bear interest at a rate tied to Acadia’s Consolidated Leverage Ratio (defined as consolidated funded debt net of up to $40.0 million of unrestricted and unencumbered cash to consolidated EBITDA, in each case as defined in the Amended and Restated Credit Agreement). The Applicable Rate (as defined in the Amended and Restated Credit Agreement) for the Pro Rata Facilities was 3.0% for Eurodollar Rate Loans (as defined in the Amended and Restated Credit Agreement) and 2.25% for Base Rate Loans (as defined in the Amended and Restated Credit Agreement) at September 30, 2015. Eurodollar Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the Eurodollar Rate (as defined in the Amended and Restated Credit Agreement) (based upon the LIBOR Rate (as defined in the Amended and Restated Credit Agreement) prior to commencement of the interest rate period). Base Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As of September 30, 2015, the Pro Rata Facilities bore interest at a rate of LIBOR plus 3.0%. In addition, the Company is required to pay a commitment fee on undrawn amounts under the revolving line of credit. Borrowings under the Pro Rata Facilities mature on February 13, 2019.

The Amended and Restated Credit Agreement requires the Company and its subsidiaries to comply with customary affirmative, negative and financial covenants, including a fixed charge coverage ratio, consolidated leverage ratio and senior secured leverage ratio. The Company may be required to pay all of its indebtedness immediately if it defaults on any of the numerous financial or other restrictive covenants contained in any of its material debt agreements. As of September 30, 2015, the Company was in compliance with such covenants.

12.875% Senior Notes due 2018

On November 1, 2011, the Company issued $150.0 million of 12.875% Senior Notes due 2018 (the “12.875% Senior Notes”) at 98.323% of the aggregate principal amount of $150.0 million, a discount of $2.5 million. The notes bear interest at a rate of 12.875% per annum. The Company pays interest on the notes semi-annually, in arrears, on November 1 and May 1 of each year.

The indenture governing the 12.875% Senior Notes contains covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

The 12.875% Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

On March 12, 2013, the Company redeemed $52.5 million in principal amount of the 12.875% Senior Notes using a portion of the net proceeds of its December 2012 equity offering pursuant to the provision in the indenture permitting an optional redemption with equity proceeds of up to 35% of the principal amount of 12.875% Senior Notes. The 12.875% Senior Notes were redeemed at a redemption price of 112.875% of the principal amount thereof plus accrued and unpaid interest to, but not including, the redemption date in accordance with the provisions of the indenture governing the 12.875% Senior Notes. As part of the redemption of 35% of the 12.875% Senior Notes, the Company recorded a debt extinguishment charge of $9.4 million, including the premium and write-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of income.

On September 21, 2015, the Company purchased approximately $88.3 million aggregate principal amount of 12.875% Senior Notes in connection with a tender offer for any and all of the 12.875% Senior Notes. The notes purchased represent 90.6% of the outstanding $97.5 million principal amount of 12.875% Senior Notes. The 12.875% Senior Notes were purchased at a price of 107.875% of the principal amount thereof plus accrued and unpaid interest to, but not including, September 21, 2015. In connection with the purchase of notes, the Company recorded a debt extinguishment charge of approximately $10.0 million, including the premium and write-off of deferred financing costs, which was recorded in debt extinguishment costs in the accompanying consolidated statements of income. On September 18, 2015, the Company delivered a notice to redeem all $9.2 million in principal amount of the 12.875% Senior Notes remaining outstanding following the consummation of the tender offer. The redemption was effective November 1, 2015 with payment made to the note holders on November 2, 2015. The Company redeemed the remaining 12.875% Senior Notes in accordance to their terms.

6.125% Senior Notes due 2021

On March 12, 2013, the Company issued $150.0 million of 6.125% Senior Notes due 2021 (the “6.125% Senior Notes”). The 6.125% Senior Notes mature on March 15, 2021 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year.

The indenture governing the 6.125% Senior Notes contains covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

The 6.125% Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the 6.125% Senior Notes at its option, in whole or part, at any time prior to March 15, 2016, at a price equal to 100% of the principal amount of the 6.125% Senior Notes redeemed, plus accrued and unpaid interest to the redemption date and plus an applicable premium. The Company may redeem the 6.125% Senior Notes, in whole or in part, on or after March 15, 2016, at the redemption prices set forth in the indenture governing the 6.125% Senior Notes plus accrued and unpaid interest to the redemption date. At any time on or before March 15, 2016, the Company may elect to redeem up to 35% of the aggregate principal amount of the 6.125% Senior Notes at a redemption price equal to 106.125% of the principal amount thereof, plus accrued and unpaid interest to the redemption date, with the net proceeds of one or more equity offerings.

5.125% Senior Notes due 2022

On July 1, 2014, the Company issued $300.0 million of 5.125% Senior Notes (the “5.125% Senior Notes”). The 5.125% Senior Notes mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year, beginning on January 1, 2015.

The indenture governing the 5.125% Senior Notes contains covenants that limit, among other things, the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets and (vii) create liens on assets.

The 5.125% Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the 5.125% Senior Notes at its option, in whole or part, at any time prior to July 1, 2017, at a price equal to 100% of the principal amount of the 5.125% Senior Notes redeemed, plus accrued and unpaid interest to the redemption date and plus an applicable premium. The Company may redeem the 5.125% Senior Notes, in whole or in part, on or after July 1, 2017, at the redemption prices set forth in the indenture governing the 5.125% Senior Notes plus accrued and unpaid interest to the redemption date. At any time on or before July 1, 2017, the Company may elect to redeem up to 35% of the aggregate principal amount of the 5.125% Senior Notes at a redemption price equal to 105.125% of the principal amount thereof, plus accrued and unpaid interest to the redemption date, with the net proceeds of one or more equity offerings.

5.625% Senior Notes due 2023

On February 11, 2015, the Company issued $375.0 million of 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”). The 5.625% Senior Notes mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year, beginning on August 15, 2015.

On September 21, 2015, the Company issued $275.0 million of additional 5.625% Senior Notes. The additional notes form a single class of debt securities with the existing 5.625% Senior Notes. Giving effect to this issuance, the Company has outstanding an aggregate of $650.0 million of 5.625% Senior Notes.

The indenture governing the 5.625% Senior Notes contains covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets and (vii) create liens on assets.

The 5.625% Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the 5.625% Senior Notes at its option, in whole or part, at any time prior to February 15, 2018, at a price equal to 100% of the principal amount of the 5.625% Senior Notes redeemed, plus accrued and unpaid interest to the redemption date and plus an applicable premium. The Company may redeem the 5.625% Senior Notes, in whole or in part, on or after February 15, 2018, at the redemption prices set forth in the indenture governing the 5.625% Senior Notes plus accrued and unpaid interest to the redemption date. At any time on or before February 15, 2018, the Company may elect to redeem up to 35% of the aggregate principal amount of the 5.625% Senior Notes at a redemption price equal to 105.625% of the principal amount thereof, plus accrued and unpaid interest to the redemption date, with the net proceeds of one or more equity offerings.

9.0% and 9.5% Revenue Bonds

On November 11, 2012, in connection with the acquisition of Park Royal, the Company assumed debt of $23.0 million. The fair market value of the debt assumed was $25.6 million and resulted in a debt premium balance being recorded as of the acquisition date. The debt consisted of $7.5 million and $15.5 million of Lee County (Florida) Industrial Development Authority Healthcare Facilities Revenue Bonds, Series 2010 with stated interest rates of 9.0% and 9.5% (“9.0% and 9.5% Revenue Bonds”), respectively. The 9.0% bonds in the amount of $7.5 million have a maturity date of December 1, 2030 and require yearly principal payments beginning in 2013. The 9.5% bonds in the amount of $15.5 million have a maturity date of December 1, 2040 and require yearly principal payments beginning in 2031. The principal payments establish a bond sinking fund to be held with the trustee and shall be sufficient to redeem the principal amounts of the 9.0% and 9.5% Revenue Bonds on their respective maturity dates. As of September 30, 2015 and December 31, 2014, $2.3 million was recorded within other assets on the balance sheet related to the debt service reserve fund requirements. The yearly principal payments, which establish a bond sinking fund, will increase the debt service reserve fund requirements. The bond premium amount of $2.6 million is amortized as a reduction of interest expense over the life of the revenue bonds using the effective interest method.

Equity Offerings

9 Months Ended

Sep. 30, 2015

Equity [Abstract]

Equity Offerings

7.	Equity Offerings

On June 17, 2014, the Company completed the offering of 8,881,794 shares of common stock (including shares sold pursuant to the exercise of the over-allotment option that the Company granted to the underwriters as part of the offering) at a price of $44.00 per share. The net proceeds to the Company from the sale of the shares, after deducting the underwriting discount of $15.6 million and additional offering-related costs of $0.8 million, were $374.4 million. The Company used the net offering proceeds to fund a portion of the consideration for the acquisition of Partnerships in Care.

On February 11, 2015, the Company completed its acquisition of CRC for total consideration of approximately $1.3 billion. As consideration for the acquisition, the Company issued 5,975,326 shares of its common stock to certain holders of CRC common stock and repaid CRC’s outstanding indebtedness.

On May 11, 2015, the Company completed the offering of 5,175,000 shares of common stock (including shares sold pursuant to the exercise of the over-allotment option that the Company granted to the underwriters as part of the offering) at a price of $66.50 per share. The net proceeds to the Company from the sale of the shares, after deducting the underwriting discount of $12.0 million and additional offering-related costs of $0.6 million, were $331.5 million. The Company used the net offering proceeds to repay outstanding indebtedness and fund acquisitions.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Equity-Based Compensation

9 Months Ended

Sep. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Equity-Based Compensation

8.	Equity-Based Compensation

Equity Incentive Plans

The Company issues stock-based awards, including stock options, restricted stock and restricted stock units, to certain officers, employees and non-employee directors under the Acadia Healthcare Company, Inc. Incentive Compensation Plan (the “Equity Incentive Plan”). As of September 30, 2015, a maximum of 4,700,000 shares of the Company’s common stock were authorized for issuance as stock options, restricted stock and restricted stock units or other share-based compensation under the Equity Incentive Plan, of which 1,885,312 were available for future grant. Stock options may be granted for terms of up to ten years. The Company recognizes expense on all share-based awards on a straight-line basis over the requisite service period of the entire award. Grants to employees generally vest in annual increments of 25% each year, commencing one year after the date of grant. The exercise prices of stock options are equal to the most recent closing price of the Company’s common stock on the date of grant.

The Company recognized $5.3 million and $2.8 million in equity-based compensation expense for the three months ended September 30, 2015 and 2014, respectively, and $14.6 million and $7.0 million for the nine months ended September 30, 2015 and 2014, respectively. As of September 30, 2015, there was $53.0 million of unrecognized compensation expense related to unvested options, restricted stock and restricted stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.5 years. The Company recognized a deferred income tax benefit of $2.2 million and $1.1 million for the three months ended September 30, 2015 and 2014, respectively, related to equity-based compensation expense. The Company recognized a deferred income tax benefit of $6.0 million and $2.8 million for the nine months ended September 30, 2015 and 2014, respectively, related to equity-based compensation expense. The actual tax benefit realized from stock options exercised during the three months ended September 30, 2015 and 2014 was $1.7 million and $0.3 million, respectively. The actual tax benefit realized from stock options exercised during the nine months ended September 30, 2015 and 2014 was $8.0 million and $3.8 million, respectively.

Stock option activity during 2014 and 2015 was as follows (aggregate intrinsic value in thousands):


	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2014		798,809		$	21.93		8.20	$	10,700
Options granted		226,663			49.80		9.25		209
Options exercised		(210,199	)		14.93		N/A		4,994
Options cancelled		(77,851	)		27.85		N/A		N/A

Options outstanding at December 31, 2014		737,422			32.19		8.09		14,512
Options granted		199,500			63.07		9.45		1,681
Options exercised		(204,867	)		44.65		N/A		9,554
Options cancelled		(24,500	)		45.91		N/A		N/A

Options outstanding at September 30, 2015		707,555		$	42.45		7.91	$	21,093

Options exercisable at December 31, 2014		91,947		$	28.87		6.30	$	3,326

Options exercisable at September 30, 2015		96,580		$	39.27		6.10	$	4,466

Restricted stock activity during 2014 and 2015 was as follows:


	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2014		461,697		$	24.96
Granted		468,484			48.99
Cancelled		(75,369	)		36.36
Vested		(132,784	)		22.81

Unvested at December 31, 2014		722,028		$	39.77
Granted		493,052			62.67
Cancelled		(33,850	)		49.15
Vested		(214,234	)		36.37

Unvested at September 30, 2015		966,996		$	51.89

Restricted stock unit activity during 2014 and 2015 was as follows:


	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2014		95,751		$	23.05
Granted		108,449			50.75
Cancelled		—			—
Vested		(79,087	)		21.81

Unvested at December 31, 2014		125,113		$	38.73
Granted		217,994			61.77
Cancelled		—			—
Vested		(125,023	)		32.38

Unvested at September 30, 2015		218,084		$	56.97

The grant-date fair value of the Company’s stock options is estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the nine months ended September 30, 2015 and year ended December 31, 2014:


	September 30, 2015			December 31, 2014
Weighted average grant-date fair value of options	$	21.79		$	17.14
Risk-free interest rate		1.53	%		1.7	%
Expected volatility		35	%		36	%
Expected life (in years)		5.5			5.5

The Company’s estimate of expected volatility for stock options is based upon the volatility of guideline companies given the lack of sufficient historical trading experience of the Company’s common stock. The risk-free interest rate is the approximate yield on United States Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised.

Income Taxes

9 Months Ended

Sep. 30, 2015

Income Tax Disclosure [Abstract]

Income Taxes

9.	Income Taxes

The provision for income taxes for continuing operations for the three months ended September 30, 2015 and 2014 reflects effective tax rates of 30.4% and 23.2%, respectively. The provision for income taxes for continuing operations for the nine months ended September 30, 2015 and 2014 reflects effective tax rates of 31.0% and 33.3%, respectively. The lower tax rate for the three months ended September 30, 2014 was primarily attributable to the tax impact of the Partnerships in Care acquisition. The lower tax rate for the nine months ended September 30, 2015 was primarily attributable to the increase in the Company’s percentage of foreign earnings, which are derived from facilities located in a lower taxing jurisdiction and are permanently reinvested.

Derivatives

9 Months Ended

Sep. 30, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivatives

10.

Derivatives

The Company entered into foreign currency forward contracts during the three and nine months ended September 30, 2015 and 2014 in connection with acquisitions in the United Kingdom. The foreign currency forward contracts limited the economic risk of changes in the foreign exchange rate between U.S. Dollars (“USD”) and British Pounds (“GBP”) associated with the payment of the purchase price in GBP. These foreign currency forward contracts did not meet the hedge accounting criteria under Accounting Standards Codification 815, Derivatives and Hedging. As such, losses associated with changes in fair value of $1.0 million and $1.9 million for the three and nine months ended September 30, 2015, respectively, have been recorded in the consolidated statements of income. The final fair value of the 2015 foreign currency forward contracts settled during the three and nine months ended September 30, 2015. Gains associated with changes in fair value of $1.5 million and $15.3 million for the three and nine months ended September 30, 2014 have been recorded in the consolidated statements of income. The final fair value of the 2014 foreign currency forward contracts settled on July 1, 2014 for $15.3 million in connection with the acquisition of Partnerships in Care.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Fair Value Measurements

9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value Measurements

11.

Fair Value Measurements

The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments.

The carrying amounts and fair values of the Company’s Amended and Restated Senior Credit Facility, 12.875% Senior Notes, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 9.0% and 9.5% Revenue Bonds and contingent consideration liabilities as of September 30, 2015 and December 31, 2014 were as follows (in thousands):


	Carrying Amount				Fair Value
	September 30, 2015		December 31, 2014		September 30, 2015		December 31, 2014
Amended and Restated Senior Credit Facility	$	999,892	$	525,576	$	999,892	$	525,576
12.875% Senior Notes due 2018	$	9,101	$	96,420	$	9,738	$	109,688
6.125% Senior Notes due 2021	$	150,000	$	150,000	$	156,000	$	153,000
5.125% Senior Notes due 2022	$	300,000	$	300,000	$	295,500	$	295,500
5.625% Senior Notes due 2023	$	651,375		—	$	654,632		—
9.0% and 9.5% Revenue Bonds	$	23,945	$	24,274	$	23,945	$	24,274
Contingent consideration liabilities	$	2,000	$	3,000	$	2,000	$	3,000

The Company’s Amended and Restated Senior Credit Facility, 12.875% Senior Notes, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 9.0% and 9.5% Revenue Bonds were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company’s lenders and the average bid and ask price as determined using published rates.

The fair value of the contingent consideration liabilities were categorized as Level 3 in the GAAP fair value hierarchy. The contingent consideration liabilities were valued using a probability-weighted discounted cash flow method. This analysis reflected the contractual terms of the purchase agreements and utilized assumptions with regard to future earnings, probabilities of achieving such future earnings and a discount rate. Significant increases with respect to assumptions as to future earnings and probabilities of achieving such future earnings would result in higher fair value measurement while an increase in the discount rate would result in a lower fair value measurement. During the nine months ended September 30, 2014, the Company changed its projections of the timing of future payments of the contingent consideration liability related to the acquisition of The Pavilion at Healthpark LLC (“Park Royal”). This change resulted in a $0.5 million increase in the fair value of the contingent consideration liability, which was recorded in transaction-related expenses in the consolidated statements of income. During the year ended December 31, 2014, the Company paid $5.0 million of the estimated $7.0 million Park Royal contingent consideration liability as a result of the facility achieving certain earnings targets.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Commitments and Contingencies

9 Months Ended

Sep. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

12.

Commitments and Contingencies

The Company is, from time to time, subject to various claims and legal actions that arise in the ordinary course of the Company’s business, including claims for damages for personal injuries, medical malpractice, breach of contract, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In the opinion of management, the Company is not currently a party to any proceeding that would individually or in the aggregate have a material adverse effect on the Company’s business, financial condition or results of operations.

Segment Information

9 Months Ended

Sep. 30, 2015

Segment Reporting [Abstract]

Segment Information

13.

Segment Information

The Company operates in one line of business, which is operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. As management reviews the operating results of its facilities in the United States (the “U.S. Facilities”) and its facilities in the United Kingdom (the “U.K. Facilities”) separately to assess performance and make decisions, the Company’s operating segments include its U.S. Facilities and U.K. Facilities. At September 30, 2015, the U.S. Facilities included 181 behavioral healthcare facilities with approximately 7,500 beds in 37 states and Puerto Rico, and the U.K. Facilities included 52 behavioral healthcare facilities with approximately 2,100 beds in the United Kingdom.

The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income from continuing operations before income taxes (in thousands):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
Revenue:
U.S. Facilities	$	379,857		$	217,427		$	1,037,250		$	630,825
U.K. Facilities		97,875			76,026			256,117			76,026
Corporate and Other		1,998			1,026			5,806			2,849

	$	479,730		$	294,479		$	1,299,173		$	709,700

Segment EBITDA (1):
U.S. Facilities	$	101,636		$	53,814		$	280,342		$	154,377
U.K. Facilities		23,015			20,253			62,197			20,253
Corporate and Other		(16,183	)		(9,001	)		(49,556	)		(25,568	)

	$	108,468		$	65,066		$	292,983		$	149,062


	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
Segment EBITDA (1)	$	108,468		$	65,066		$	292,983		$	149,062
Plus (less):
Equity-based compensation expense		(5,327	)		(2,805	)		(14,576	)		(6,975	)
Debt extinguishment costs		(9,979	)		—			(9,979	)		—
(Loss) gain on foreign currency derivatives		(1,018	)		1,527			(1,926	)		15,262
Transaction-related expenses		(5,842	)		(6,239	)		(31,415	)		(10,834	)
Interest expense, net		(27,737	)		(14,068	)		(77,932	)		(33,505	)
Depreciation and amortization		(16,890	)		(10,325	)		(44,920	)		(21,696	)

Income from continuing operations before income taxes	$	41,675		$	33,156		$	112,235		$	91,314


	U.S. Facilities			U.K. Facilities			Corporate and Other			Consolidated
Goodwill:
Balance at January 1, 2015	$	693,945		$	109,041		$	—		$	802,986
Increase from 2015 acquisitions		1,114,683			89,859			—			1,204,542
Foreign currency translation		—			736			—			736
Purchase price allocation and other		281			(27,405	)		—			(27,124	)

Balance at September 30, 2015	$	1,808,909		$	172,231		$	—		$	1,981,140


	September 30, 2015		December 31, 2014
Assets (2):
U.S. Facilities	$	2,848,415	$	1,327,563
U.K. Facilities		1,032,804		726,693
Corporate and Other		264,020		169,334

	$	4,145,239	$	2,223,590

(1)

Segment EBITDA is defined as income from continuing operations before provision for income taxes, equity-based compensation expense, debt extinguishment costs, gain/loss on foreign currency derivatives, transaction-related expenses, interest expense and depreciation and amortization. The Company uses Segment EBITDA as an analytical indicator to measure the performance of the Company’s segments and to develop strategic objectives and operating plans for those segments. Segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Segment EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and the items excluded from Segment EBITDA are significant components in understanding and assessing financial performance. Because Segment EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, Segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.

(2)

Assets include property and equipment for the U.S. Facilities of $759.2 million, U.K. Facilities of $820.7 million and corporate and other of $44.3 million at September 30, 2015. Assets include property and equipment for the U.S. Facilities of $478.1 million, U.K. Facilities of $578.6 million and corporate and other of $13.0 million at December 31, 2014.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

Recently Issued Accounting Standards

9 Months Ended

Sep. 30, 2015

Accounting Changes and Error Corrections [Abstract]

Recently Issued Accounting Standards

14.

Recently Issued Accounting Standards

In September 2015, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2015-16, “Business Combinations (Subtopic 805-10)” (“ASU 2015-16”). ASU 2015-16 simplifies the accounting for measurement-period adjustments by eliminating the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Acquirers will recognize measurement-period adjustments during the period in which they determine the amounts, including the effect on earnings of any amounts they would have recorded in previous periods if the accounting had been completed at the acquisition date. Although this guidance has an effective date for public companies for fiscal years, and interim periods within those years, beginning after December 15, 2015, the Company has elected early adoption as permitted in the current period. As a result, there is no significant impact on the Company’s consolidated financial statements.

In April 2015, the FASB issued ASU 2015-03, “Interest-Imputation of Interest (Subtopic 835-30)” (“ASU 2015-03”). ASU 2015-03 simplifies the presentation of debt issuance costs by requiring debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, and the new guidance should be applied retrospectively. Management is evaluating the impact of ASU 2015-03 on the Company’s consolidated financial statements.

In May 2014, the FASB and the International Accounting Standards Board issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09’s core principal is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Additionally, ASU 2014-09 would permit both public and nonpublic organizations to adopt the new revenue standard early, but not before the original public organization effective date (that is, annual periods beginning after December 15, 2016). Management is evaluating the impact of ASU 2014-09 on the Company’s consolidated financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305

+ Details

Subsequent Events

9 Months Ended

Sep. 30, 2015

Subsequent Events [Abstract]

Subsequent Events

15.

Subsequent Events

On October 1, 2015, the Company completed the acquisition of Meadow View (“Meadow View”), an inpatient psychiatric facility with 28 beds located in England, for cash consideration of approximately $6.9 million. On November 1, 2015, the Company completed the acquisitions of (i) Discovery House-Group, Inc. (“Discovery House”) for cash consideration of approximately $118.5 million, (ii) Duffy’s Napa Valley Rehab (“Duffy’s”) for cash consideration of approximately $29.6 million and (iii) Cleveland House (“Cleveland House”) for approximately $10.2 million. Discovery House operates 19 comprehensive treatment centers located in four states. Duffy’s is a substance abuse facility with 61 beds located in Calistoga, California. Cleveland House is an inpatient psychiatric facility with 32 beds located in England.

Financial Information for the Company and Its Subsidiaries

9 Months Ended

Sep. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Financial Information for the Company and Its Subsidiaries

16.

Financial Information for the Company and Its Subsidiaries

The Company conducts substantially all of its business through its subsidiaries. The 12.875% Senior Notes, 6.125% Senior Notes, 5.125% Senior Notes and 5.625% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by all of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. Presented below is condensed consolidating financial information for the Company and its subsidiaries as of September 30, 2015 and December 31, 2014, and for the three and nine months ended September 30, 2015 and 2014. The information segregates the parent company (Acadia Healthcare Company, Inc.), the combined wholly-owned subsidiary guarantors, the combined non-guarantor subsidiaries and eliminations.

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

September 30, 2015

(In thousands)


	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	46,865	$	3,897	$	—		$	50,762
Accounts receivable, net		—		182,815		32,068		—			214,883
Deferred tax assets		—		35,471		1,820		—			37,291
Other current assets		—		66,930		8,405		—			75,335

Total current assets		—		332,081		46,190		—			378,271
Property and equipment, net		—		731,670		892,496		—			1,624,166
Goodwill		—		1,702,375		278,765		—			1,981,140
Intangible assets, net		—		56,411		2,565		—			58,976
Deferred tax assets – noncurrent		4,621		18,484		10,173		—			33,278
Investment in subsidiaries		1,256,878		—		—		(1,256,878	)		—
Other assets		462,205		28,488		2,322		(423,607	)		69,408

Total assets	$	1,723,704	$	2,869,509	$	1,232,511	$	(1,680,485	)	$	4,145,239

Current liabilities:
Current portion of long-term debt	$	41,781	$	—	$	215	$	—		$	41,996
Accounts payable		—		64,748		13,636		—			78,384
Accrued salaries and benefits		—		72,979		14,131		—			87,110
Other accrued liabilities		11,371		19,592		25,999		—			56,962

Total current liabilities		53,152		157,319		53,981		—			264,452
Long-term debt		—		2,068,588		447,336		(423,607	)		2,092,317
Deferred tax liabilities – noncurrent		—		—		22,210		—			22,210
Other liabilities		—		77,687		9,321		—			87,008

Total liabilities		53,152		2,303,594		532,848		(423,607	)		2,465,987

Redeemable noncontrolling interests		—		—		8,700		—			8,700

Total equity		1,670,552		565,915		690,963		(1,256,878	)		1,670,552

Total liabilities and equity	$	1,723,704	$	2,869,509	$	1,232,511	$	(1,680,485	)	$	4,145,239

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2014

(In thousands)


	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	76,685	$	17,355	$	—		$	94,040
Accounts receivable, net		—		100,797		17,581		—			118,378
Deferred tax assets		—		18,395		1,760		—			20,155
Other current assets		—		36,049		5,521		—			41,570

Total current assets		—		231,926		42,217		—			274,143
Property and equipment, net		—		451,943		617,757		—			1,069,700
Goodwill		—		596,611		206,375		—			802,986
Intangible assets, net		—		19,057		2,579		—			21,636
Deferred tax assets – noncurrent		4,563		—		14,244		(5,666	)		13,141
Investment in subsidiaries		1,759,337		—		—		(1,759,337	)		—
Other assets		202,708		18,727		2,323		(181,774	)		41,984

Total assets	$	1,966,608	$	1,318,264	$	885,495	$	(1,946,777	)	$	2,223,590

Current liabilities:
Current portion of long-term debt	$	26,750	$	—	$	215	$	—		$	26,965
Accounts payable		—		39,486		9,210		—			48,696
Accrued salaries and benefits		—		47,597		11,720		—			59,317
Other accrued liabilities		13,647		7,688		9,621		—			30,956

Total current liabilities		40,397		94,771		30,766		—			165,934
Long-term debt		1,045,246		—		205,833		(181,774	)		1,069,305
Deferred tax liabilities – noncurrent		—		21,027		48,519		(5,666	)		63,880
Other liabilities		—		33,321		10,185		—			43,506

Total liabilities		1,085,643		149,119		295,303		(187,440	)		1,342,625

Total equity		880,965		1,169,145		590,192		(1,759,337	)		880,965

Total liabilities and equity	$	1,966,608	$	1,318,264	$	885,495	$	(1,946,777	)	$	2,223,590

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended September 30, 2015

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	377,582		$	111,164		$	—		$	488,746
Provision for doubtful accounts		—			(8,531	)		(485	)		—			(9,016	)

Revenue		—			369,051			110,679			—			479,730
Salaries, wages and benefits		5,327			191,032			62,051			—			258,410
Professional fees		—			21,551			9,208			—			30,759
Supplies		—			17,349			4,285			—			21,634
Rents and leases		—			7,624			918			—			8,542
Other operating expenses		—			47,113			10,131			—			57,244
Depreciation and amortization		—			10,578			6,312			—			16,890
Interest expense, net		15,934			6,036			5,767			—			27,737
Debt extinguishment costs		9,979			—			—			—			9,979
Loss on foreign currency derivatives		1,018			—			—			—			1,018
Transaction-related expenses		—			2,831			3,011			—			5,842

Total expenses		32,258			304,114			101,683			—			438,055
(Loss) income from continuing operations before income taxes		(32,258	)		64,937			8,996			—			41,675
Equity in earnings of subsidiaries		50,840			—			—			(50,840	)		—
(Benefit from) provision for income taxes		(10,504	)		21,383			1,790			—			12,669

Income (loss) from continuing operations		29,086			43,554			7,206			(50,840	)		29,006
Income from discontinued operations, net of income taxes		—			80			—			—			80

Net income (loss)		29,086			43,634			7,206			(50,840	)		29,086
Net loss attributable to noncontrolling interests		—			—			464			—			464

Net income attributable to Acadia Healthcare Company, Inc.	$	29,086		$	43,634		$	7,670		$	(50,840	)	$	29,550

Other comprehensive income:
Foreign currency translation gain		—			—			(32,707	)		—			(32,707	)

Other comprehensive income		—			—			(32,707	)		—			(32,707	)

Comprehensive income (loss)	$	29,086		$	43,634		$	(25,037	)	$	(50,840	)	$	(3,157	)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended September 30, 2014

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	212,376		$	90,625		$	—		$	303,001
Provision for doubtful accounts		—			(7,444	)		(1,078	)		—			(8,522	)

Revenue		—			204,932			89,547			—			294,479
Salaries, wages and benefits		2,805			117,261			48,566			—			168,632
Professional fees		—			9,816			5,062			—			14,878
Supplies		—			10,784			3,278			—			14,062
Rents and leases		—			2,419			795			—			3,214
Other operating expenses		—			18,979			12,453			—			31,432
Depreciation and amortization		—			5,874			4,451			—			10,325
Interest expense, net		4,096			6,439			3,533			—			14,068
Gain on foreign currency derivatives		(1,527	)		—			—			—			(1,527	)
Transaction-related expenses		—			5,428			811			—			6,239

Total expenses		5,374			177,000			78,949			—			261,323
(Loss) income from continuing operations before income taxes		(5,374	)		27,932			10,598			—			33,156
Equity in earnings of subsidiaries		28,607			—			—			(28,607	)		—
(Benefit from) provision for income taxes		(2,169	)		12,517			(2,645	)		—			7,703

Income (loss) from continuing operations		25,402			15,415			13,243			(28,607	)		25,453
Income from discontinued operations, net of income taxes		—			(51	)		—			—			(51	)

Net income (loss)	$	25,402		$	15,364		$	13,243		$	(28,607	)	$	25,402

Other comprehensive income:
Foreign currency translation gain		—			—			(36,857	)		—			(36,857	)

Other comprehensive income		—			—			(36,857	)		—			(36,857	)

Comprehensive income (loss)	$	25,402		$	15,364		$	(23,614	)	$	(28,607	)	$	(11,455	)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Nine Months Ended September 30, 2015

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	1,029,198		$	295,504		$	—		$	1,324,702
Provision for doubtful accounts		—			(23,516	)		(2,013	)		—			(25,529	)

Revenue		—			1,005,682			293,491			—			1,299,173
Salaries, wages and benefits		14,576			530,221			162,786			—			707,583
Professional fees		—			60,615			22,600			—			83,215
Supplies		—			47,287			11,143			—			58,430
Rents and leases		—			20,143			2,496			—			22,639
Other operating expenses		—			122,505			26,394			—			148,899
Depreciation and amortization		—			29,840			15,080			—			44,920
Interest expense, net		46,988			17,639			13,305			—			77,932
Debt extinguishment costs		9,979			—			—			—			9,979
Loss on foreign currency derivatives		1,926			—			—			—			1,926
Transaction-related expenses		—			24,193			7,222			—			31,415

Total expenses		73,469			852,443			261,026			—			1,186,938
(Loss) income from continuing operations before income taxes		(73,469	)		153,239			32,465			—			112,235
Equity in earnings of subsidiaries		127,108			—			—			(127,108	)		—
(Benefit from) provision for income taxes		(23,885	)		50,634			8,045			—			34,794

Income (loss) from continuing operations		77,524			102,605			24,420			(127,108	)		77,441
Income from discontinued operations, net of income taxes		—			83			—			—			83

Net income (loss)		77,524			102,688			24,420			(127,108	)		77,524
Net loss attributable to noncontrolling interests		—			—			464			—			464

Net income attributable to Acadia Healthcare Company, Inc.	$	77,524		$	102,688		$	24,884		$	(127,108	)	$	77,988

Other comprehensive income:
Foreign currency translation gain		—			—			(15,923	)		—			(15,923	)

Other comprehensive income		—			—			(15,923	)		—			(15,923	)

Comprehensive income (loss)	$	77,524		$	102,688		$	8,961		$	(127,108	)	$	62,065

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Nine Months Ended September 30, 2014

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	612,801		$	116,983		$	—		$	729,784
Provision for doubtful accounts		—			(17,908	)		(2,176	)		—			(20,084	)

Revenue		—			594,893			114,807			—			709,700
Salaries, wages and benefits		6,975			342,890			58,815			—			408,680
Professional fees		—			28,760			7,391			—			36,151
Supplies		—			30,137			4,585			—			34,722
Rents and leases		—			7,527			1,345			—			8,872
Other operating expenses		—			62,579			16,609			—			79,188
Depreciation and amortization		—			16,540			5,156			—			21,696
Interest expense, net		22,409			6,439			4,657			—			33,505
Loss on foreign currency derivatives		(15,262	)		—			—			—			(15,262	)
Transaction-related expenses		—			10,023			811			—			10,834

Total expenses		14,122			504,895			99,369			—			618,386
(Loss) income from continuing operations before income taxes		(14,122	)		89,998			15,438			—			91,314
Equity in earnings of subsidiaries		69,446			—			—			(69,446	)		—
(Benefit from) provision for income taxes		(5,587	)		36,766			(796	)		—			30,383

Income (loss) from continuing operations		60,911			53,232			16,234			(69,446	)		60,931
Income from discontinued operations, net of income taxes		—			(20	)		—			—			(20	)

Net income (loss)	$	60,911		$	53,212		$	16,234		$	(69,446	)	$	60,911

Other comprehensive income:
Foreign currency translation gain		—			—			(36,857	)		—			(36,857	)

Other comprehensive income		—			—			(36,857	)		—			(36,857	)

Comprehensive income (loss)	$	60,911		$	53,212		$	(20,623	)	$	(69,446	)	$	24,054

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Nine Months Ended September 30, 2015

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	77,524		$	102,688		$	24,420		$	(127,108	)	$	77,524
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(127,108	)		—			—			127,108			—
Depreciation and amortization		—			29,840			15,080			—			44,920
Amortization of debt issuance costs		5,347			—			(330	)		—			5,017
Equity-based compensation expense		14,576			—			—			—			14,576
Deferred income tax (benefit) expense		(58	)		27,035			1,948			—			28,925
Loss from discontinued operations, net of taxes		—			(83	)		—			—			(83	)
Debt extinguishment costs		9,979			—			—			—			9,979
Loss (gain) on foreign currency derivatives		1,926			—			—			—			1,926
Other		—			1,088			34			—			1,122
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(16,535	)		(12,370	)		—			(28,905	)
Other current assets		—			(14,287	)		2,086			—			(12,201	)
Other assets		(300	)		(4,881	)		2			300			(4,879	)
Accounts payable and other accrued liabilities		—			(10,510	)		2,194			—			(8,316	)
Accrued salaries and benefits		—			7,953			935			—			8,888
Other liabilities		—			5,821			(750	)		—			5,071

Net cash (used in) provided by continuing operating activities		(18,114	)		128,129			33,249			300			143,564
Net cash provided by discontinued operating activities		—			(1,479	)		—			—			(1,479	)

Net cash (used in) provided by operating activities		(18,114	)		126,650			33,249			300			142,085
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(88,308	)		(302,908	)		—			(391,216	)
Cash paid for capital expenditures		—			(116,466	)		(84,375	)		—			(200,841	)
Cash paid for real estate acquisitions		—			(21,976	)		—			—			(21,976	)
Settlement of foreign currency derivatives		—			(1,926	)		—			—			(1,926	)
Other		—			(887	)		—			—			(887	)

Net cash used in investing activities		—			(229,563	)		(387,283	)		—			(616,846	)
Financing activities:
Borrowings on long-term debt		1,150,000			—			—			—			1,150,000
Borrowings on revolving credit facility		310,000			—			—			—			310,000
Principal payments on revolving credit facility		(310,000	)		—			—			—			(310,000	)
Principal payments on long-term debt		(23,813	)		—			(300	)		300			(23,813	)
Repayment of assumed CRC debt		(904,467	)		—			—			—			(904,467	)
Repayments of senior notes		(88,331	)		—			—			—			(88,331	)
Payment of debt issuance costs		(25,584	)		—			—			—			(25,584	)
Payment of premium on senior notes		(6,890	)		—			—			—			(6,890	)
Issuance of Common Stock		—			331,360			—			—			331,360
Common stock withheld for minimum statutory taxes, net		(7,582	)		—			—			—			(7,582	)
Excess tax benefit from equity awards		8,020			—			—			—			8,020
Other		—			(374	)		—			—			(374	)
Cash provided by (used in) intercompany activity		(83,239	)		(257,037	)		340,876			(600	)		—

Net cash provided by (used in) financing activities		18,114			73,949			340,576			(300	)		432,339

Effect of exchange rate changes on cash		—			(856	)		—			—			(856	)

Net (decrease) increase in cash and cash equivalents		—			(29,820	)		(13,458	)		—			(43,278	)
Cash and cash equivalents at beginning of the period		—			76,685			17,355			—			94,040

Cash and cash equivalents at end of the period	$	—		$	46,865		$	3,897		$	—		$	50,762

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Nine Months Ended September 30, 2014

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	60,911		$	53,212		$	16,234		$	(69,446	)	$	60,911
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(69,446	)		—			—			69,446			—
Depreciation and amortization		—			16,540			5,156			—			21,696
Amortization of debt issuance costs		1,891			—			338			—			2,229
Equity-based compensation expense		6,975			—			—			—			6,975
Deferred income tax expense		(754	)		3,218			2,181			—			4,645
Income from discontinued operations, net of taxes		—			20			—			—			20
Gain on foreign currency derivatives		(15,262	)		—			—			—			(15,262	)
Other		—			134			29			—			163
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(23,347	)		(2,048	)		—			(25,395	)
Other current assets		—			1,067			255			—			1,322
Other assets		165			(2,086	)		—			(165	)		(2,086	)
Accounts payable and other accrued liabilities		—			(2,752	)		3,830			—			1,078
Accrued salaries and benefits		—			6,546			2,456			—			8,972
Other liabilities		—			3,549			256			—			3,805

Net cash (used in) provided by continuing operating activities		(15,520	)		56,101			28,657			(165	)		69,073
Net cash used in discontinued operating activities		—			(27	)		—			—			(27	)

Net cash (used in) provided by operating activities		(15,520	)		56,074			28,657			(165	)		69,046
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(722,797	)		—			—			(722,797	)
Cash paid for capital expenditures		—			(60,223	)		(10,457	)		—			(70,680	)
Cash paid for real estate acquisitions		—			(22,247	)		—			—			(22,247	)
Settlement of foreign currency derivatives		15,262			—			—			—			15,262
Other		—			(733	)		—			—			(733	)

Net cash used in investing activities		15,262			(806,000	)		(10,457	)		—			(801,195	)
Financing activities:
Borrowings on long-term debt		307,500			—			—			—			307,500
Borrowings on revolving credit facility		230,500			—			—			—			230,500
Principal payments on revolving credit facility		(120,000	)		—			—			—			(120,000	)
Principal payments on long-term debt		(5,625	)		—			(165	)		165			(5,625	)
Payment of debt issuance costs		(10,909	)		—			—			—			(10,909	)
Issuance of common stock, net		374,431			—			—			—			374,431
Common stock withheld for minimum statutory taxes, net		(3,477	)		—			—			—			(3,477	)
Excess tax benefit from equity awards		3,779			—			—			—			3,779
Cash paid for contingent consideration		—			(5,000	)		—			—			(5,000	)
Cash (used in) provided by intercompany activity		(775,941	)		765,347			8,669			1,925			—

Net cash provided by (used in) financing activities		258			760,347			8,504			2,090			771,199

Effect of exchange rate changes on cash		—			—			(1,440	)		—			(1,440	)

Net increase (decrease) in cash and cash equivalents		—			10,421			25,264			1,925			37,610
Cash and cash equivalents at beginning of the period		—			—			6,494			(1,925	)		4,569

Cash and cash equivalents at end of the period	$	—		$	10,421		$	31,758		$	—		$	42,179

Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2015 and 2014 (in thousands, except per share amounts):


	Three Months Ended September 30,					Nine Months Ended September 30,
	2015		2014			2015		2014
Numerator:
Basic and diluted earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations	$	29,470	$	25,453		$	77,905	$	60,931
Income (loss) from discontinued operations		80		(51	)		83		(20	)

Net income	$	29,550	$	25,402		$	77,988	$	60,911

Denominator:
Weighted average shares outstanding for basic earnings per share		70,664		59,175			67,194		53,670
Effect of dilutive instruments		446		234			345		252

Shares used in computing diluted earnings per common share		71,110		59,409			67,539		53,922

Basic earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations	$	0.42	$	0.43		$	1.16	$	1.14
Income (loss) from discontinued operations		—		—			—		—

Net income	$	0.42	$	0.43		$	1.16	$	1.14

Diluted earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations	$	0.42	$	0.43		$	1.15	$	1.13
Income (loss) from discontinued operations		—		—			—		—

Net income	$	0.42	$	0.43		$	1.15	$	1.13

Acquisitions (Tables)

9 Months Ended

Sep. 30, 2015

Preliminary Fair Values of Assets Acquired and Liabilities Assumed at Corresponding Acquisition Date


	Partnerships in Care		Other		Total
Cash	$	11,674	$	—	$	11,674
Accounts receivable		7,684		1,849		9,533
Prepaid expenses and other current assets		8,828		169		8,997
Property and equipment		610,477		27,203		637,680
Goodwill		92,959		32,232		125,191
Intangible assets		651		204		855
Other assets		7,037		3,240		10,277

Total assets acquired		739,310		64,897		804,207
Accounts payable		3,958		93		4,051
Accrued salaries and benefits		10,422		—		10,422
Other accrued expenses		7,166		1,014		8,180
Deferred tax liabilities – noncurrent		21,509		—		21,509
Other liabilities		7,704		—		7,704

Total liabilities assumed		50,759		1,107		51,866

Net assets acquired	$	688,551	$	63,790	$	752,341

Transaction-related expenses comprised the following costs for the three and nine months ended September 30, 2015 and 2014 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Advisory and financing commitment fees	$	—	$	—	$	10,337	$	—
Legal, accounting and other costs		5,261		5,935		14,315		10,071
Severance and contract termination costs		581		304		6,763		763

	$	5,842	$	6,239	$	31,415	$	10,834

Pro Forma Financial Information for Acquisitions Occurred

The following table provides certain pro forma financial information for the Company as if the 2014 and 2015 Acquisitions occurred as of January 1, 2014 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Revenue	$	485,680	$	480,695	$	1,424,587	$	1,321,938

Income from continuing operations, before income taxes	$	43,101	$	47,340	$	87,511	$	91,591

CRC Health Group Inc and Other Acquisitions [Member]

Preliminary Fair Values of Assets Acquired and Liabilities Assumed at Corresponding Acquisition Date


	CRC		Other		Total
Cash	$	19,600	$	5,141	$	24,741
Accounts receivable		47,095		20,917		68,012
Prepaid expenses and other current assets		26,448		1,207		27,655
Property and equipment		137,243		241,629		378,872
Goodwill		1,052,049		152,494		1,204,543
Intangible assets		37,000		204		37,204
Deferred tax assets – noncurrent		70,375		—		70,375
Other assets		6,478		—		6,478

Total assets acquired		1,396,288		421,592		1,817,880
Accounts payable		4,752		1,960		6,712
Accrued salaries and benefits		14,889		2,658		17,547
Other accrued expenses		38,638		3,848		42,486
Deferred tax liabilities – noncurrent		—		1,357		1,357
Long-term debt		904,467		2		904,469
Other liabilities		39,967		11		39,978

Total liabilities assumed		1,002,713		9,836		1,012,549

Redeemable noncontrolling interests		—		9,164		9,164

Net assets acquired	$	393,575	$	402,592	$	796,167

Other Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Other Identifiable Intangible Assets and Related Accumulated Amortization

Other identifiable intangible assets and related accumulated amortization consisted of the following as of September 30, 2015 and December 31, 2014 (in thousands):


	Gross Carrying Amount				Accumulated Amortization
	September 30, 2015		December 31, 2014		September 30, 2015			December 31, 2014
Intangible assets subject to amortization:
Contract intangible assets	$	2,100	$	2,100	$	(1,645	)	$	(1,330	)
Non-compete agreements		1,247		1,247		(1,226	)		(1,155	)

		3,347		3,347		(2,871	)		(2,485	)

Intangible assets not subject to amortization:
Licenses and accreditations		10,779		9,184		—			—
Trade names		37,800		3,000		—			—
Certificates of need		9,921		8,590		—			—

		58,500		20,774		—			—

Total	$	61,847	$	24,121	$	(2,871	)	$	(2,485	)

Property and Equipment (Tables)

9 Months Ended

Sep. 30, 2015

Text Block [Abstract]

Summary of Property and Equipment

Property and equipment consists of the following as of September 30, 2015 and December 31, 2014 (in thousands):


	September 30, 2015			December 31, 2014
Land	$	209,297		$	132,406
Building and improvements		1,229,551			858,055
Equipment		127,275			73,584
Construction in progress		159,336			66,268

		1,725,459			1,130,313
Less accumulated depreciation		(101,293	)		(60,613	)

Property and equipment, net	$	1,624,166		$	1,069,700

Long-Term Debt (Tables)

9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Components of Long-Term Debt

Long-term debt consisted of the following (in thousands):


	September 30, 2015			December 31, 2014
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loans (net of discount of $1,501 and $1,924, respectively)	$	505,937		$	525,576
Senior Secured Term B Loans (net of discount of $2,295)		493,955			—
Senior Secured Revolving Line of Credit		—			—
12.875% Senior Notes due 2018 (net of discount of $68 and $1,080, respectively)		9,101			96,420
6.125% Senior Notes due 2021		150,000			150,000
5.125% Senior Notes due 2022		300,000			300,000
5.625% Senior Notes due 2023 (net of premium of $1,375)		651,375			—
9.0% and 9.5% Revenue Bonds (net of premium of $1,320 and $1,649, respectively)		23,945			24,274

		2,134,313			1,096,270
Less: current portion		(41,996	)		(26,965	)

Long-term debt	$	2,092,317		$	1,069,305

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Equity-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Option Activity

Stock option activity during 2014 and 2015 was as follows (aggregate intrinsic value in thousands):


	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2014		798,809		$	21.93		8.20	$	10,700
Options granted		226,663			49.80		9.25		209
Options exercised		(210,199	)		14.93		N/A		4,994
Options cancelled		(77,851	)		27.85		N/A		N/A

Options outstanding at December 31, 2014		737,422			32.19		8.09		14,512
Options granted		199,500			63.07		9.45		1,681
Options exercised		(204,867	)		44.65		N/A		9,554
Options cancelled		(24,500	)		45.91		N/A		N/A

Options outstanding at September 30, 2015		707,555		$	42.45		7.91	$	21,093

Options exercisable at December 31, 2014		91,947		$	28.87		6.30	$	3,326

Options exercisable at September 30, 2015		96,580		$	39.27		6.10	$	4,466

Restricted Stock Activity

Restricted stock activity during 2014 and 2015 was as follows:


	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2014		461,697		$	24.96
Granted		468,484			48.99
Cancelled		(75,369	)		36.36
Vested		(132,784	)		22.81

Unvested at December 31, 2014		722,028		$	39.77
Granted		493,052			62.67
Cancelled		(33,850	)		49.15
Vested		(214,234	)		36.37

Unvested at September 30, 2015		966,996		$	51.89

Restricted Stock Unit Activity

Restricted stock unit activity during 2014 and 2015 was as follows:


	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2014		95,751		$	23.05
Granted		108,449			50.75
Cancelled		—			—
Vested		(79,087	)		21.81

Unvested at December 31, 2014		125,113		$	38.73
Granted		217,994			61.77
Cancelled		—			—
Vested		(125,023	)		32.38

Unvested at September 30, 2015		218,084		$	56.97

Schedule of Stock Options Valuation Assumptions

The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the nine months ended September 30, 2015 and year ended December 31, 2014:


	September 30, 2015			December 31, 2014
Weighted average grant-date fair value of options	$	21.79		$	17.14
Risk-free interest rate		1.53	%		1.7	%
Expected volatility		35	%		36	%
Expected life (in years)		5.5			5.5

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liability


	Carrying Amount				Fair Value
	September 30, 2015		December 31, 2014		September 30, 2015		December 31, 2014
Amended and Restated Senior Credit Facility	$	999,892	$	525,576	$	999,892	$	525,576
12.875% Senior Notes due 2018	$	9,101	$	96,420	$	9,738	$	109,688
6.125% Senior Notes due 2021	$	150,000	$	150,000	$	156,000	$	153,000
5.125% Senior Notes due 2022	$	300,000	$	300,000	$	295,500	$	295,500
5.625% Senior Notes due 2023	$	651,375		—	$	654,632		—
9.0% and 9.5% Revenue Bonds	$	23,945	$	24,274	$	23,945	$	24,274
Contingent consideration liabilities	$	2,000	$	3,000	$	2,000	$	3,000

Segment Information (Tables)

9 Months Ended

Sep. 30, 2015

Summary of Reconciliation of Segment EBITDA to Income from Continuing Operations

The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income from continuing operations before income taxes (in thousands):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
Revenue:
U.S. Facilities	$	379,857		$	217,427		$	1,037,250		$	630,825
U.K. Facilities		97,875			76,026			256,117			76,026
Corporate and Other		1,998			1,026			5,806			2,849

	$	479,730		$	294,479		$	1,299,173		$	709,700

Segment EBITDA (1):
U.S. Facilities	$	101,636		$	53,814		$	280,342		$	154,377
U.K. Facilities		23,015			20,253			62,197			20,253
Corporate and Other		(16,183	)		(9,001	)		(49,556	)		(25,568	)

	$	108,468		$	65,066		$	292,983		$	149,062


	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
Segment EBITDA (1)	$	108,468		$	65,066		$	292,983		$	149,062
Plus (less):
Equity-based compensation expense		(5,327	)		(2,805	)		(14,576	)		(6,975	)
Debt extinguishment costs		(9,979	)		—			(9,979	)		—
(Loss) gain on foreign currency derivatives		(1,018	)		1,527			(1,926	)		15,262
Transaction-related expenses		(5,842	)		(6,239	)		(31,415	)		(10,834	)
Interest expense, net		(27,737	)		(14,068	)		(77,932	)		(33,505	)
Depreciation and amortization		(16,890	)		(10,325	)		(44,920	)		(21,696	)

Income from continuing operations before income taxes	$	41,675		$	33,156		$	112,235		$	91,314

Summary of Assets by Operating Segment


	September 30, 2015		December 31, 2014
Assets (2):
U.S. Facilities	$	2,848,415	$	1,327,563
U.K. Facilities		1,032,804		726,693
Corporate and Other		264,020		169,334

	$	4,145,239	$	2,223,590

Goodwill [Member]

Summary of Assets by Operating Segment


	U.S. Facilities		U.K. Facilities			Corporate and Other		Consolidated
Goodwill:
Balance at January 1, 2015	$	693,945	$	109,041		$	—	$	802,986
Increase from 2015 acquisitions		1,114,683		89,859			—		1,204,542
Foreign currency translation		—		736			—		736
Purchase price allocation and other		281		(27,405	)		—		(27,124	)

Balance at September 30, 2015	$	1,808,909	$	172,231		$	—	$	1,981,140

Financial Information for the Company and Its Subsidiaries (Tables)

9 Months Ended

Sep. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Condensed Consolidating Balance Sheets

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

September 30, 2015

(In thousands)


	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	46,865	$	3,897	$	—		$	50,762
Accounts receivable, net		—		182,815		32,068		—			214,883
Deferred tax assets		—		35,471		1,820		—			37,291
Other current assets		—		66,930		8,405		—			75,335

Total current assets		—		332,081		46,190		—			378,271
Property and equipment, net		—		731,670		892,496		—			1,624,166
Goodwill		—		1,702,375		278,765		—			1,981,140
Intangible assets, net		—		56,411		2,565		—			58,976
Deferred tax assets – noncurrent		4,621		18,484		10,173		—			33,278
Investment in subsidiaries		1,256,878		—		—		(1,256,878	)		—
Other assets		462,205		28,488		2,322		(423,607	)		69,408

Total assets	$	1,723,704	$	2,869,509	$	1,232,511	$	(1,680,485	)	$	4,145,239

Current liabilities:
Current portion of long-term debt	$	41,781	$	—	$	215	$	—		$	41,996
Accounts payable		—		64,748		13,636		—			78,384
Accrued salaries and benefits		—		72,979		14,131		—			87,110
Other accrued liabilities		11,371		19,592		25,999		—			56,962

Total current liabilities		53,152		157,319		53,981		—			264,452
Long-term debt		—		2,068,588		447,336		(423,607	)		2,092,317
Deferred tax liabilities – noncurrent		—		—		22,210		—			22,210
Other liabilities		—		77,687		9,321		—			87,008

Total liabilities		53,152		2,303,594		532,848		(423,607	)		2,465,987

Redeemable noncontrolling interests		—		—		8,700		—			8,700

Total equity		1,670,552		565,915		690,963		(1,256,878	)		1,670,552

Total liabilities and equity	$	1,723,704	$	2,869,509	$	1,232,511	$	(1,680,485	)	$	4,145,239

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2014

(In thousands)


	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	76,685	$	17,355	$	—		$	94,040
Accounts receivable, net		—		100,797		17,581		—			118,378
Deferred tax assets		—		18,395		1,760		—			20,155
Other current assets		—		36,049		5,521		—			41,570

Total current assets		—		231,926		42,217		—			274,143
Property and equipment, net		—		451,943		617,757		—			1,069,700
Goodwill		—		596,611		206,375		—			802,986
Intangible assets, net		—		19,057		2,579		—			21,636
Deferred tax assets – noncurrent		4,563		—		14,244		(5,666	)		13,141
Investment in subsidiaries		1,759,337		—		—		(1,759,337	)		—
Other assets		202,708		18,727		2,323		(181,774	)		41,984

Total assets	$	1,966,608	$	1,318,264	$	885,495	$	(1,946,777	)	$	2,223,590

Current liabilities:
Current portion of long-term debt	$	26,750	$	—	$	215	$	—		$	26,965
Accounts payable		—		39,486		9,210		—			48,696
Accrued salaries and benefits		—		47,597		11,720		—			59,317
Other accrued liabilities		13,647		7,688		9,621		—			30,956

Total current liabilities		40,397		94,771		30,766		—			165,934
Long-term debt		1,045,246		—		205,833		(181,774	)		1,069,305
Deferred tax liabilities – noncurrent		—		21,027		48,519		(5,666	)		63,880
Other liabilities		—		33,321		10,185		—			43,506

Total liabilities		1,085,643		149,119		295,303		(187,440	)		1,342,625

Total equity		880,965		1,169,145		590,192		(1,759,337	)		880,965

Total liabilities and equity	$	1,966,608	$	1,318,264	$	885,495	$	(1,946,777	)	$	2,223,590

Summary of Condensed Consolidating Statement of Comprehensive Income (Loss)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended September 30, 2015

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	377,582		$	111,164		$	—		$	488,746
Provision for doubtful accounts		—			(8,531	)		(485	)		—			(9,016	)

Revenue		—			369,051			110,679			—			479,730
Salaries, wages and benefits		5,327			191,032			62,051			—			258,410
Professional fees		—			21,551			9,208			—			30,759
Supplies		—			17,349			4,285			—			21,634
Rents and leases		—			7,624			918			—			8,542
Other operating expenses		—			47,113			10,131			—			57,244
Depreciation and amortization		—			10,578			6,312			—			16,890
Interest expense, net		15,934			6,036			5,767			—			27,737
Debt extinguishment costs		9,979			—			—			—			9,979
Loss on foreign currency derivatives		1,018			—			—			—			1,018
Transaction-related expenses		—			2,831			3,011			—			5,842

Total expenses		32,258			304,114			101,683			—			438,055
(Loss) income from continuing operations before income taxes		(32,258	)		64,937			8,996			—			41,675
Equity in earnings of subsidiaries		50,840			—			—			(50,840	)		—
(Benefit from) provision for income taxes		(10,504	)		21,383			1,790			—			12,669

Income (loss) from continuing operations		29,086			43,554			7,206			(50,840	)		29,006
Income from discontinued operations, net of income taxes		—			80			—			—			80

Net income (loss)		29,086			43,634			7,206			(50,840	)		29,086
Net loss attributable to noncontrolling interests		—			—			464			—			464

Net income attributable to Acadia Healthcare Company, Inc.	$	29,086		$	43,634		$	7,670		$	(50,840	)	$	29,550

Other comprehensive income:
Foreign currency translation gain		—			—			(32,707	)		—			(32,707	)

Other comprehensive income		—			—			(32,707	)		—			(32,707	)

Comprehensive income (loss)	$	29,086		$	43,634		$	(25,037	)	$	(50,840	)	$	(3,157	)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended September 30, 2014

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	212,376		$	90,625		$	—		$	303,001
Provision for doubtful accounts		—			(7,444	)		(1,078	)		—			(8,522	)

Revenue		—			204,932			89,547			—			294,479
Salaries, wages and benefits		2,805			117,261			48,566			—			168,632
Professional fees		—			9,816			5,062			—			14,878
Supplies		—			10,784			3,278			—			14,062
Rents and leases		—			2,419			795			—			3,214
Other operating expenses		—			18,979			12,453			—			31,432
Depreciation and amortization		—			5,874			4,451			—			10,325
Interest expense, net		4,096			6,439			3,533			—			14,068
Gain on foreign currency derivatives		(1,527	)		—			—			—			(1,527	)
Transaction-related expenses		—			5,428			811			—			6,239

Total expenses		5,374			177,000			78,949			—			261,323
(Loss) income from continuing operations before income taxes		(5,374	)		27,932			10,598			—			33,156
Equity in earnings of subsidiaries		28,607			—			—			(28,607	)		—
(Benefit from) provision for income taxes		(2,169	)		12,517			(2,645	)		—			7,703

Income (loss) from continuing operations		25,402			15,415			13,243			(28,607	)		25,453
Income from discontinued operations, net of income taxes		—			(51	)		—			—			(51	)

Net income (loss)	$	25,402		$	15,364		$	13,243		$	(28,607	)	$	25,402

Other comprehensive income:
Foreign currency translation gain		—			—			(36,857	)		—			(36,857	)

Other comprehensive income		—			—			(36,857	)		—			(36,857	)

Comprehensive income (loss)	$	25,402		$	15,364		$	(23,614	)	$	(28,607	)	$	(11,455	)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Nine Months Ended September 30, 2015

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	1,029,198		$	295,504		$	—		$	1,324,702
Provision for doubtful accounts		—			(23,516	)		(2,013	)		—			(25,529	)

Revenue		—			1,005,682			293,491			—			1,299,173
Salaries, wages and benefits		14,576			530,221			162,786			—			707,583
Professional fees		—			60,615			22,600			—			83,215
Supplies		—			47,287			11,143			—			58,430
Rents and leases		—			20,143			2,496			—			22,639
Other operating expenses		—			122,505			26,394			—			148,899
Depreciation and amortization		—			29,840			15,080			—			44,920
Interest expense, net		46,988			17,639			13,305			—			77,932
Debt extinguishment costs		9,979			—			—			—			9,979
Loss on foreign currency derivatives		1,926			—			—			—			1,926
Transaction-related expenses		—			24,193			7,222			—			31,415

Total expenses		73,469			852,443			261,026			—			1,186,938
(Loss) income from continuing operations before income taxes		(73,469	)		153,239			32,465			—			112,235
Equity in earnings of subsidiaries		127,108			—			—			(127,108	)		—
(Benefit from) provision for income taxes		(23,885	)		50,634			8,045			—			34,794

Income (loss) from continuing operations		77,524			102,605			24,420			(127,108	)		77,441
Income from discontinued operations, net of income taxes		—			83			—			—			83

Net income (loss)		77,524			102,688			24,420			(127,108	)		77,524
Net loss attributable to noncontrolling interests		—			—			464			—			464

Net income attributable to Acadia Healthcare Company, Inc.	$	77,524		$	102,688		$	24,884		$	(127,108	)	$	77,988

Other comprehensive income:
Foreign currency translation gain		—			—			(15,923	)		—			(15,923	)

Other comprehensive income		—			—			(15,923	)		—			(15,923	)

Comprehensive income (loss)	$	77,524		$	102,688		$	8,961		$	(127,108	)	$	62,065

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Nine Months Ended September 30, 2014

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	612,801		$	116,983		$	—		$	729,784
Provision for doubtful accounts		—			(17,908	)		(2,176	)		—			(20,084	)

Revenue		—			594,893			114,807			—			709,700
Salaries, wages and benefits		6,975			342,890			58,815			—			408,680
Professional fees		—			28,760			7,391			—			36,151
Supplies		—			30,137			4,585			—			34,722
Rents and leases		—			7,527			1,345			—			8,872
Other operating expenses		—			62,579			16,609			—			79,188
Depreciation and amortization		—			16,540			5,156			—			21,696
Interest expense, net		22,409			6,439			4,657			—			33,505
Loss on foreign currency derivatives		(15,262	)		—			—			—			(15,262	)
Transaction-related expenses		—			10,023			811			—			10,834

Total expenses		14,122			504,895			99,369			—			618,386
(Loss) income from continuing operations before income taxes		(14,122	)		89,998			15,438			—			91,314
Equity in earnings of subsidiaries		69,446			—			—			(69,446	)		—
(Benefit from) provision for income taxes		(5,587	)		36,766			(796	)		—			30,383

Income (loss) from continuing operations		60,911			53,232			16,234			(69,446	)		60,931
Income from discontinued operations, net of income taxes		—			(20	)		—			—			(20	)

Net income (loss)	$	60,911		$	53,212		$	16,234		$	(69,446	)	$	60,911

Other comprehensive income:
Foreign currency translation gain		—			—			(36,857	)		—			(36,857	)

Other comprehensive income		—			—			(36,857	)		—			(36,857	)

Comprehensive income (loss)	$	60,911		$	53,212		$	(20,623	)	$	(69,446	)	$	24,054

Summary of Condensed Consolidating Statement of Cash Flows

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Nine Months Ended September 30, 2015

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	77,524		$	102,688		$	24,420		$	(127,108	)	$	77,524
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(127,108	)		—			—			127,108			—
Depreciation and amortization		—			29,840			15,080			—			44,920
Amortization of debt issuance costs		5,347			—			(330	)		—			5,017
Equity-based compensation expense		14,576			—			—			—			14,576
Deferred income tax (benefit) expense		(58	)		27,035			1,948			—			28,925
Loss from discontinued operations, net of taxes		—			(83	)		—			—			(83	)
Debt extinguishment costs		9,979			—			—			—			9,979
Loss (gain) on foreign currency derivatives		1,926			—			—			—			1,926
Other		—			1,088			34			—			1,122
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(16,535	)		(12,370	)		—			(28,905	)
Other current assets		—			(15,602	)		2,086			—			(13,516	)
Other assets		(300	)		(4,881	)		2			300			(4,879	)
Accounts payable and other accrued liabilities		—			(11,984	)		2,194			—			(9,790	)
Accrued salaries and benefits		—			7,953			935			—			8,888
Other liabilities		—			5,821			(750	)		—			5,071

Net cash (used in) provided by continuing operating activities		(18,114	)		125,340			33,249			300			140,775
Net cash provided by discontinued operating activities		—			1,310			—			—			1,310

Net cash (used in) provided by operating activities		(18,114	)		126,650			33,249			300			142,085
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(88,308	)		(302,908	)		—			(391,216	)
Cash paid for capital expenditures		—			(116,466	)		(84,375	)		—			(200,841	)
Cash paid for real estate acquisitions		—			(21,976	)		—			—			(21,976	)
Settlement of foreign currency derivatives		—			(1,926	)		—			—			(1,926	)
Other		—			(887	)		—			—			(887	)

Net cash used in investing activities		—			(229,563	)		(387,283	)		—			(616,846	)
Financing activities:
Borrowings on long-term debt		1,150,000			—			—			—			1,150,000
Borrowings on revolving credit facility		310,000			—			—			—			310,000
Principal payments on revolving credit facility		(310,000	)		—			—			—			(310,000	)
Principal payments on long-term debt		(23,813	)		—			(300	)		300			(23,813	)
Repayment of assumed CRC debt		(904,467	)		—			—			—			(904,467	)
Repayments of senior notes		(88,331	)		—			—			—			(88,331	)
Payment of debt issuance costs		(25,584	)		—			—			—			(25,584	)
Payment of premium on senior notes		(6,890	)		—			—			—			(6,890	)
Issuance of Common Stock		—			331,360			—			—			331,360
Common stock withheld for minimum statutory taxes, net		(7,582	)		—			—			—			(7,582	)
Excess tax benefit from equity awards		8,020			—			—			—			8,020
Other		—			(374	)		—			—			(374	)
Cash provided by (used in) intercompany activity		(83,239	)		(257,037	)		340,876			(600	)		—

Net cash provided by (used in) financing activities		18,114			73,949			340,576			(300	)		432,339

Effect of exchange rate changes on cash		—			(856	)		—			—			(856	)

Net (decrease) increase in cash and cash equivalents		—			(29,820	)		(13,458	)		—			(43,278	)
Cash and cash equivalents at beginning of the period		—			76,685			17,355			—			94,040

Cash and cash equivalents at end of the period	$	—		$	46,865		$	3,897		$	—		$	50,762

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Nine Months Ended September 30, 2014

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	60,911		$	53,212		$	16,234		$	(69,446	)	$	60,911
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(69,446	)		—			—			69,446			—
Depreciation and amortization		—			16,540			5,156			—			21,696
Amortization of debt issuance costs		1,891			—			338			—			2,229
Equity-based compensation expense		6,975			—			—			—			6,975
Deferred income tax expense		(754	)		3,218			2,181			—			4,645
Income from discontinued operations, net of taxes		—			20			—			—			20
Gain on foreign currency derivatives		(15,262	)		—			—			—			(15,262	)
Other		—			134			29			—			163
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(23,347	)		(2,048	)		—			(25,395	)
Other current assets		—			1,067			255			—			1,322
Other assets		165			(2,086	)		—			(165	)		(2,086	)
Accounts payable and other accrued liabilities		—			(2,752	)		3,830			—			1,078
Accrued salaries and benefits		—			6,546			2,456			—			8,972
Other liabilities		—			3,549			256			—			3,805

Net cash (used in) provided by continuing operating activities		(15,520	)		56,074			28,657			(165	)		69,073
Net cash used in discontinued operating activities		—			(27	)		—			—			(27	)

Net cash (used in) provided by operating activities		(15,520	)		56,074			28,657			(165	)		69,046
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(722,797	)		—			—			(722,797	)
Cash paid for capital expenditures		—			(60,223	)		(10,457	)		—			(70,680	)
Cash paid for real estate acquisitions		—			(22,247	)		—			—			(22,247	)
Settlement of foreign currency derivatives		15,262			—			—			—			15,262
Other		—			(733	)		—			—			(733	)

Net cash used in investing activities		15,262			(806,000	)		(10,457	)		—			(801,195	)
Financing activities:
Borrowings on long-term debt		307,500			—			—			—			307,500
Borrowings on revolving credit facility		230,500			—			—			—			230,500
Principal payments on revolving credit facility		(120,000	)		—			—			—			(120,000	)
Principal payments on long-term debt		(5,625	)		—			(165	)		165			(5,625	)
Payment of debt issuance costs		(10,909	)		—			—			—			(10,909	)
Issuance of common stock, net		374,431			—			—			—			374,431
Common stock withheld for minimum statutory taxes, net		(3,477	)		—			—			—			(3,477	)
Excess tax benefit from equity awards		3,779			—			—			—			3,779
Cash paid for contingent consideration		—			(5,000	)		—			—			(5,000	)
Cash (used in) provided by intercompany activity		(775,941	)		765,347			8,669			1,925			—

Net cash provided by (used in) financing activities		258			760,347			8,504			2,090			771,199

Effect of exchange rate changes on cash		—			—			(1,440	)		—			(1,440	)

Net increase (decrease) in cash and cash equivalents		—			10,421			25,264			1,925			37,610
Cash and cash equivalents at beginning of the period		—			—			6,494			(1,925	)		4,569

Cash and cash equivalents at end of the period	$	—		$	10,421		$	31,758		$	—		$	42,179

Description of Business and Basis of Presentation - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2015 Beds State Facilities
Accounting Policies [Abstract]
Number of facilities \| Facilities	233
Number of beds \| Beds	9,600
Number of operating states \| State	37

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Basic and diluted earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations	$ 29,470	$ 25,453	$ 77,905	$ 60,931
Income (loss) from discontinued operations	80	(51)	83	(20)
Net income attributable to Acadia Healthcare Company, Inc.	$ 29,550	$ 25,402	$ 77,988	$ 60,911
Denominator:
Weighted average shares outstanding for basic earnings per share	70,664	59,175	67,194	53,670
Effect of dilutive instruments	446	234	345	252
Shares used in computing diluted earnings per common share	71,110	59,409	67,539	53,922
Basic earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations	$ 0.42	$ 0.43	$ 1.16	$ 1.14
Income (loss) from discontinued operations	0	0	0	0
Net income	0.42	0.43	1.16	1.14
Diluted earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations	0.42	0.43	1.15	1.13
Income (loss) from discontinued operations	0	0	0	0
Net income	$ 0.42	$ 0.43	$ 1.15	$ 1.13

Earnings Per Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Earnings Per Share [Abstract]
Excluded common stock for computation of diluted earnings per share	0.3	0.5	0.9	0.7

Acquisitions - UK Acquisitions - Additional Information (Detail) - United Kingdom [Member] $ in Millions	Sep. 01, 2015 USD ($) Beds Facility	Jul. 01, 2015 USD ($) Beds	Jun. 01, 2015 USD ($) Beds Facility	Apr. 01, 2015 USD ($) Beds Facility
The Danshell Group [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $	$ 59.8
Number of facilities acquired \| Facility	3
Number of beds \| Beds	73
Health and Social Care Partnerships [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $	$ 26.2
Number of facilities acquired \| Facility	2
Number of beds \| Beds	50
Manor Hall [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $	$ 14.0
Number of beds \| Beds	26
The Manor Clinic [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $		$ 5.9
Number of beds \| Beds		15
Care UK Limited [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $			$ 88.2
Number of facilities acquired \| Facility			15
Number of beds \| Beds			299
Choice Lifestyles [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $			$ 25.9	$ 37.5
Number of facilities acquired \| Facility			1	2
Number of beds \| Beds			42	48
Pastoral Care Group [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $				$ 34.2
Number of facilities acquired \| Facility				2
Number of beds \| Beds				65
Mildmay Oaks [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $				$ 14.9
Number of beds \| Beds				67

Acquisitions - Southcoast - Additional Information (Detail) - Massachusetts [Member] - Southcoast Behavioral [Member] $ in Millions	Aug. 31, 2015 USD ($)
Business Acquisition [Line Items]
Approximate value of noncontrolling interest	$ 9.2
Equity ownership interests percentage in the facility	75.00%
Percentage of noncontrolling interests in the facility	25.00%

Acquisitions - Belmont - Additional Information (Detail) - Pennsylvania [Member] - Belmont Behavioral Health [Member] $ in Millions	Jul. 01, 2015 USD ($) Beds
Business Acquisition [Line Items]
Number of beds \| Beds	147
Business acquisition cash paid	$ 40.0
Total consideration related to acquisition	35.0
Estimated working capital settlement	$ 5.0

Acquisitions - Recent Acquisitions - Additional Information (Detail) - Quality Addiction Management [Member] $ in Millions	Mar. 01, 2015 USD ($) Center
Business Acquisition [Line Items]
Business acquisition cash paid \| $	$ 54.6
Number of facilities acquired \| Center	7

Acquisitions - CRC Acquisition - Additional Information (Detail) $ in Millions	Feb. 11, 2015 USD ($) Beds State Center Facilities shares	Sep. 30, 2015 State
Business Acquisition [Line Items]
Number of operating states \| State		37
CRC Health Group, Inc [Member]
Business Acquisition [Line Items]
Total consideration related to acquisition \| $	$ 1,300.0
Shares issued for acquisition \| shares	5,975,326
Outstanding indebtedness of CRC repaid \| $	$ 904.5
Number of inpatient facilities \| Facilities	35
Number of operating states \| State	30
Number of facilities acquired \| Center	81
Minimum [Member] \| CRC Health Group, Inc [Member]
Business Acquisition [Line Items]
Number of beds \| Beds	2,400

Acquisitions - 2014 Acquisitions - Additional Information (Detail) $ in Thousands						3 Months Ended		9 Months Ended
	Dec. 31, 2014 USD ($) Beds	Dec. 01, 2014 USD ($) Beds	Sep. 03, 2014 USD ($) Beds	Jul. 01, 2014 USD ($) Beds Facilities	Jan. 01, 2014 USD ($) Beds	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)
Business Acquisition [Line Items]
Gain on foreign currency derivatives						$ (1,018)	$ 1,527	$ (1,926)	$ 15,262
Croxton [Member] \| 2014 Acquisitions [Member]
Business Acquisition [Line Items]
Business acquisition cash paid		$ 15,600
Number of beds \| Beds		24
Skyway [Member] \| 2014 Acquisitions [Member]
Business Acquisition [Line Items]
Business acquisition cash paid	$ 300
Number of beds \| Beds	28
Acquisition completion date	Dec. 31, 2014
McCallum [Member] \| 2014 Acquisitions [Member]
Business Acquisition [Line Items]
Business acquisition cash paid			$ 37,400
Number of beds \| Beds			85
Partnerships In Care [Member] \| 2014 Acquisitions [Member]
Business Acquisition [Line Items]
Acquisition completion date				Jul. 01, 2014
Number of inpatient psychiatric facilities \| Facilities				23
Total consideration related to acquisition				$ 661,700
Cash from consideration related to acquisition				12,000
Gain on foreign currency derivatives				$ 15,300
Partnerships In Care [Member] \| Minimum [Member] \| 2014 Acquisitions [Member]
Business Acquisition [Line Items]
Number of beds \| Beds				1,200
Pacific Grove [Member] \| 2014 Acquisitions [Member]
Business Acquisition [Line Items]
Business acquisition cash paid					$ 10,500
Number of beds \| Beds					68

Acquisitions - Summary of Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill associated with domestic acquisitions	$ 1,981,140	$ 802,986
Domestic Acquisitions in 2015 and 2014 [Member]
Business Acquisition [Line Items]
Goodwill associated with domestic acquisitions	$ 174,500	$ 174,500

Acquisitions - Summary of Acquisitions (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill	$ 1,981,140	$ 802,986
2014 Acquisitions [Member]
Business Acquisition [Line Items]
Cash		11,674
Accounts receivable		9,533
Prepaid expenses and other current assets		8,997
Property and equipment		637,680
Goodwill		125,191
Intangible assets		855
Other assets		10,277
Total assets acquired		804,207
Accounts payable		4,051
Accrued salaries and benefits		10,422
Other accrued expenses		8,180
Deferred tax liabilities - noncurrent		21,509
Other liabilities		7,704
Total liabilities assumed		51,866
Net assets acquired		752,341
2015 Acquisitions [Member]
Business Acquisition [Line Items]
Cash	24,741
Accounts receivable	68,012
Prepaid expenses and other current assets	27,655
Property and equipment	378,872
Goodwill	1,204,543
Intangible assets	37,204
Deferred tax assets - noncurrent	70,375
Other assets	6,478
Total assets acquired	1,817,880
Accounts payable	6,712
Accrued salaries and benefits	17,547
Other accrued expenses	42,486
Deferred tax liabilities - noncurrent	1,357
Long-term debt	904,469
Other liabilities	39,978
Total liabilities assumed	1,012,549
Redeemable noncontrolling interests	9,164
Net assets acquired	796,167
Partnerships In Care [Member] \| 2014 Acquisitions [Member]
Business Acquisition [Line Items]
Cash		11,674
Accounts receivable		7,684
Prepaid expenses and other current assets		8,828
Property and equipment		610,477
Goodwill		92,959
Intangible assets		651
Other assets		7,037
Total assets acquired		739,310
Accounts payable		3,958
Accrued salaries and benefits		10,422
Other accrued expenses		7,166
Deferred tax liabilities - noncurrent		21,509
Other liabilities		7,704
Total liabilities assumed		50,759
Net assets acquired		688,551
Other [Member] \| 2014 Acquisitions [Member]
Business Acquisition [Line Items]
Accounts receivable		1,849
Prepaid expenses and other current assets		169
Property and equipment		27,203
Goodwill		32,232
Intangible assets		204
Other assets		3,240
Total assets acquired		64,897
Accounts payable		93
Other accrued expenses		1,014
Total liabilities assumed		1,107
Net assets acquired		$ 63,790
Other [Member] \| 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Cash	5,141
Accounts receivable	20,917
Prepaid expenses and other current assets	1,207
Property and equipment	241,629
Goodwill	152,494
Intangible assets	204
Total assets acquired	421,592
Accounts payable	1,960
Accrued salaries and benefits	2,658
Other accrued expenses	3,848
Deferred tax liabilities - noncurrent	1,357
Long-term debt	2
Other liabilities	11
Total liabilities assumed	9,836
Redeemable noncontrolling interests	9,164
Net assets acquired	402,592
CRC Health Group, Inc [Member] \| 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Cash	19,600
Accounts receivable	47,095
Prepaid expenses and other current assets	26,448
Property and equipment	137,243
Goodwill	1,052,049
Intangible assets	37,000
Deferred tax assets - noncurrent	70,375
Other assets	6,478
Total assets acquired	1,396,288
Accounts payable	4,752
Accrued salaries and benefits	14,889
Other accrued expenses	38,638
Long-term debt	904,467
Other liabilities	39,967
Total liabilities assumed	1,002,713
Net assets acquired	$ 393,575

Acquisitions - Other (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Acquisitions - Other (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Business Combinations [Abstract]
Advisory and financing commitment fees			$ 10,337
Legal, accounting and other costs	$ 5,261	$ 5,935	14,315	$ 10,071
Severance and contract termination costs	581	304	6,763	763
Transaction-related expenses	$ 5,842	$ 6,239	$ 31,415	$ 10,834

Acquisitions - Pro Forma Information - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Business Acquisition [Line Items]
Revenue	$ 479,730	$ 294,479	$ 1,299,173	$ 709,700
Income from continuing operations before income taxes	41,675	33,156	112,235	91,314
Acquisitions Completed in 2014 And 2015 [Member]
Business Acquisition [Line Items]
Revenue	250,000		619,700
Income from continuing operations before income taxes	$ 37,500		$ 95,200
Acquisitions Completed in 2014 [Member]
Business Acquisition [Line Items]
Revenue		78,800		81,800
Income from continuing operations before income taxes		$ 6,200		$ 6,100

Acquisitions - Pro Forma Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Business Combinations [Abstract]
Revenue	$ 485,680	$ 480,695	$ 1,424,587	$ 1,321,938
Income from continuing operations, before income taxes	$ 43,101	$ 47,340	$ 87,511	$ 91,591

Other Intangible Assets - Other Identifiable Intangible Assets and Related Accumulated Amortization (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	$ 3,347	$ 3,347
Intangible assets not subject to amortization, Gross Carrying Amount	58,500	20,774
Total	61,847	24,121
Intangible assets subject to amortization, Accumulated Amortization	(2,871)	(2,485)
Contract Intangible Assets [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	2,100	2,100
Intangible assets subject to amortization, Accumulated Amortization	(1,645)	(1,330)
Non-Compete Agreements [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	1,247	1,247
Intangible assets subject to amortization, Accumulated Amortization	(1,226)	(1,155)
Licenses and Accreditations [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	10,779	9,184
Trade Names [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	37,800	3,000
Certificates of Need [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	$ 9,921	$ 8,590

Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Amortization expense	$ 0.1	$ 0.1	$ 0.4	$ 0.4
Estimated amortization expense, remainder of 2015	0.5		0.5
Estimated amortization expense, 2016	0.4		0.4
Estimated amortization expense, 2017	0.0		0.0
Estimated amortization expense, 2018	0.0		0.0
Estimated amortization expense, 2019	$ 0.0		0.0
Licenses and Accreditations [Member] \| CRC Health Group, Inc [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Acquisition of intangible assets with a preliminary fair value			1.1
Trade Names [Member] \| CRC Health Group, Inc [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Acquisition of intangible assets with a preliminary fair value			34.8
Certificates of Need [Member] \| CRC Health Group, Inc [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Acquisition of intangible assets with a preliminary fair value			$ 1.1

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,725,459	$ 1,130,313
Less accumulated depreciation	(101,293)	(60,613)
Property and equipment, net	1,624,166	1,069,700
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	209,297	132,406
Building and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,229,551	858,055
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	127,275	73,584
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 159,336	$ 66,268

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 21, 2015	Sep. 18, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term debt	$ 2,134,313			$ 1,096,270
Long-term debt	2,134,313			1,096,270
Less: current portion	(41,996)			(26,965)
Long-term debt	2,092,317			1,069,305
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term A Loans [Member]
Debt Instrument [Line Items]
Senior Secured	505,937			525,576
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term B Loans [Member]
Debt Instrument [Line Items]
Senior Secured	493,955
12.875% Senior Notes Due 2018 [Member]
Debt Instrument [Line Items]
Senior Notes	9,101		$ 9,200	96,420
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Senior Notes	150,000			150,000
5.125% Senior Notes due 2022 [Member]
Debt Instrument [Line Items]
Senior Notes	300,000			300,000
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Senior Notes	651,375	$ 650,000
9.0% and 9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 23,945			$ 24,274

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013	Nov. 01, 2011
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term A Loans [Member]
Debt Instrument [Line Items]
Debt instrument discount	$ 1,501	$ 1,924
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term B Loans [Member]
Debt Instrument [Line Items]
Debt instrument discount	2,295
12.875% Senior Notes Due 2018 [Member]
Debt Instrument [Line Items]
Debt instrument discount	$ 68	$ 1,080					$ 2,500
Debt instrument interest rate	12.875%	12.875%	12.875%			12.875%	12.875%
Senior notes maturity year	2018	2018
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%				6.125%
Senior notes maturity year	2021	2021
5.125% Senior Notes due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%	5.125%			5.125%
Senior notes maturity year	2022	2022
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%	5.625%	5.625%
Senior notes maturity year	2023	2023
Debt instrument premium	$ 1,375
9.0% and 9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument premium	$ 1,320	$ 1,649
9.0% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.00%	9.00%
9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.50%	9.50%

Long-Term Debt (Amended and Restated Senior Credit Facility) - Additional Information (Detail) - USD ($)						3 Months Ended				9 Months Ended
	Dec. 15, 2014	Jun. 16, 2014	Feb. 13, 2014	Dec. 31, 2012	Apr. 01, 2011	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Feb. 11, 2015	Feb. 06, 2015
Debt Instrument [Line Items]
Quarterly term loan principal payment										$ 310,000,000	$ 120,000,000
Amended and Restated Senior Credit Facility [Member]
Debt Instrument [Line Items]
Date entered into an agreement	Dec. 15, 2014		Feb. 13, 2014	Dec. 31, 2012	Apr. 01, 2011
Restrictive covenants on investments, Description										The Company may now invest in non-wholly owned subsidiaries and joint ventures up to 7.5% of the Company’s and its subsidiaries’ total assets in any fiscal year, and up to 10% of the Company’s and its subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The Company may also invest in foreign subsidiaries that are not loan parties up to 10% of the Company’s and its subsidiaries’ total assets in any fiscal year, and up to 15% of the Company’s and its subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The foregoing permitted investments are subject to an aggregate cap of 20% of the Company’s and its subsidiaries’ total assets in any fiscal year.
Amount available under revolving line of credit										$ 293,700,000
Debt instrument maturity date	Feb. 13, 2019									Feb. 11, 2022
Quarterly term loan principal payment	$ 1,900,000
Term loan repayments						$ 1,300,000
Consolidated funded debt, unrestricted and unencumbered cash to consolidated EBITDA	40,000,000
Amended and Restated Senior Credit Facility [Member] \| Miscellaneous Investments [Member]
Debt Instrument [Line Items]
Date entered into an agreement		Jun. 16, 2014
Amended and Restated Senior Credit Facility [Member] \| Scenario, Plan [Member]
Debt Instrument [Line Items]
Additional term loans			$ 150,000,000
Line of Credit Facility, Increase (Decrease) for Period, Description										The Fourth Amendment also provides for a $150.0 million incremental credit facility, with the potential for unlimited additional incremental amounts, provided the Company meets certain financial ratios, in each case subject to customary conditions precedent to borrowing.
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term A Loans [Member]
Debt Instrument [Line Items]
Line of credit			300,000,000
Additional term loans	235,000,000
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit			$ 300,000,000
Amended and Restated Senior Credit Facility [Member] \| Seventh Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement										Feb. 06, 2015
Amended and Restated Senior Credit Facility [Member] \| Letter of Credit [Member] \| Seventh Amendment [Member]
Debt Instrument [Line Items]
Line of credit													$ 20,000,000
Amended and Restated Senior Credit Facility [Member] \| Swing Line Sublimit [Member] \| Seventh Amendment [Member]
Debt Instrument [Line Items]
Line of credit													$ 20,000,000
Amended and Restated Senior Credit Facility [Member] \| Eurodollar [Member]
Debt Instrument [Line Items]
Interest on borrowings										3.00%
Basis spread on variable rate										1.00%
Amended and Restated Senior Credit Facility [Member] \| Base Rate Loans [Member]
Debt Instrument [Line Items]
Interest on borrowings										2.25%
Basis spread on variable rate										0.50%
Amended and Restated Senior Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Interest on borrowings										3.00%
Amended and Restated Senior Credit Facility [Member] \| Senior Debt Obligations [Member] \| First Incremental Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement										Feb. 11, 2015
Line of credit												$ 500,000,000
Amended and Restated Senior Credit Facility [Member] \| September 30, 2015 to December 31, 2015 [Member]
Debt Instrument [Line Items]
Term loan principal repayments	6,700,000
Term loan repayments									$ 1,300,000
Amended and Restated Senior Credit Facility [Member] \| March 31, 2016 to December 31, 2016 [Member]
Debt Instrument [Line Items]
Term loan principal repayments	10,000,000
Term loan repayments								$ 1,300,000
Amended and Restated Senior Credit Facility [Member] \| September 30, 2017 to December 31, 2017 [Member]
Debt Instrument [Line Items]
Term loan principal repayments	13,400,000
Term loan repayments							$ 1,300,000
Amended and Restated Senior Credit Facility [Member] \| March 31, 2018 to December 31, 2018 [Member]
Debt Instrument [Line Items]
Term loan principal repayments	16,700,000
Amended and Restated Senior Credit Facility [Member] \| CRC Health Group, Inc [Member] \| Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Temporary reserve	$ 110,000,000

Long-Term Debt (12.875% Senior Notes due 2018) - Additional Information (Detail) - USD ($) $ in Thousands				3 Months Ended	9 Months Ended
	Sep. 21, 2015	Sep. 18, 2015	Mar. 12, 2013	Sep. 30, 2015	Sep. 30, 2015	Dec. 31, 2014	Nov. 01, 2011
Debt Instrument [Line Items]
Debt extinguishment charge				$ (9,979)	$ (9,979)
Purchase of senior notes					88,331
12.875% Senior Notes Due 2018 [Member]
Debt Instrument [Line Items]
Issued Senior Notes	$ 97,500						$ 150,000
Issue rate of senior notes							98.323%
Debt instrument discount				$ 68	$ 68	$ 1,080	$ 2,500
Senior notes interest percentage	12.875%		12.875%	12.875%	12.875%	12.875%	12.875%
Interest on the notes					Semi-annually, in arrears, on November 1 and May 1 of each year
Debt instrument, maximum redemption amount			$ 52,500
Debt instrument, purchase price percentage	107.875%		112.875%
Purchase percentage of senior notes	90.60%		35.00%
Debt extinguishment charge	$ 10,000		$ 9,400
Purchase of senior notes	$ 88,300
Senior notes, redemption beginning period		Nov. 01, 2015
Senior Notes		$ 9,200		$ 9,101	$ 9,101	$ 96,420

Long-Term Debt (6.125% Senior Notes due 2021) - Additional Information (Detail) - 6.125% Senior Notes Due 2021 [Member] - USD ($) $ in Millions		9 Months Ended
	Mar. 12, 2013	Sep. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Issued Senior Notes	$ 150.0
Debt instrument interest rate	6.125%	6.125%	6.125%
Debt instrument maturity date	Mar. 15, 2021
Interest on the notes		Payable semi-annually in arrears on March 15 and September 15 of each year.
Senior notes terms		The Company may redeem the 6.125% Senior Notes at its option, in whole or part, at any time prior to March 15, 2016, at a price equal to 100% of the principal amount of the 6.125% Senior Notes redeemed, plus accrued and unpaid interest to the redemption date and plus an applicable premium. The Company may redeem the 6.125% Senior Notes, in whole or in part, on or after March 15, 2016, at the redemption prices set forth in the indenture governing the 6.125% Senior Notes plus accrued and unpaid interest to the redemption date. At any time on or before March 15, 2016, the Company may elect to redeem up to 35% of the aggregate principal amount of the 6.125% Senior Notes at a redemption price equal to 106.125% of the principal amount thereof, plus accrued and unpaid interest to the redemption date, with the net proceeds of one or more equity offerings.
Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price percentage		100.00%
Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price percentage		106.125%
Redemption percentage of senior notes		35.00%
Redemption date		Mar. 15, 2016

Long-Term Debt (5.125% Senior Notes due 2022) - Additional Information (Detail) - 5.125% Senior Notes due 2022 [Member] - USD ($) $ in Millions		9 Months Ended
	Jul. 01, 2014	Sep. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Issued Senior Notes	$ 300.0
Debt instrument interest rate	5.125%	5.125%	5.125%
Debt instrument maturity date	Jul. 01, 2022
Interest on the notes		Payable semi-annually in arrears on January 1 and July 1 of each year, beginning on January 1, 2015.
Senior notes terms		The Company may redeem the 5.125% Senior Notes at its option, in whole or part, at any time prior to July 1, 2017, at a price equal to 100% of the principal amount of the 5.125% Senior Notes redeemed, plus accrued and unpaid interest to the redemption date and plus an applicable premium. The Company may redeem the 5.125% Senior Notes, in whole or in part, on or after July 1, 2017, at the redemption prices set forth in the indenture governing the 5.125% Senior Notes plus accrued and unpaid interest to the redemption date. At any time on or before July 1, 2017, the Company may elect to redeem up to 35% of the aggregate principal amount of the 5.125% Senior Notes at a redemption price equal to 105.125% of the principal amount thereof, plus accrued and unpaid interest to the redemption date, with the net proceeds of one or more equity offerings.
Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price percentage		100.00%
Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price percentage		105.125%
Redemption percentage of senior notes		35.00%
Redemption date		Jul. 01, 2017

Long-Term Debt (5.625% Senior Notes due 2023) - Additional Information (Detail) - 5.625% Senior Notes Due 2023 [Member] - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 21, 2015	Feb. 11, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Issued Senior Notes		$ 275,000	$ 375,000
Debt instrument interest rate	5.625%	5.625%	5.625%	5.625%
Debt instrument maturity date	Feb. 15, 2023
Date of initial payments on senior notes	Aug. 15, 2015
Senior Notes	$ 651,375	$ 650,000
Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price percentage	100.00%
Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price percentage	105.625%
Redemption percentage of senior notes	35.00%
Redemption date	Feb. 15, 2018

Long-Term Debt (9.0% and 9.5% Revenue Bonds) - Additional Information (Detail) - USD ($) $ in Thousands	Nov. 11, 2012	Sep. 30, 2015	Dec. 31, 2014
9.0% and 9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds		$ 23,945	$ 24,274
Debt instrument premium		1,320	1,649
9.0% and 9.5% Revenue Bonds [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 23,000
Debt service reserve fund within other assets		$ 2,300	$ 2,300
Debt instrument premium	2,600
9.0% and 9.5% Revenue Bonds [Member] \| Fair Value Measurement [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	25,600
9.0% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		9.00%	9.00%
9.0% Revenue Bonds [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 7,500
Debt instrument interest rate	9.00%
Debt instrument maturity date	Dec. 01, 2030
9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		9.50%	9.50%
9.5% Revenue Bonds [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 15,500
Debt instrument interest rate	9.50%
Debt instrument maturity date	Dec. 01, 2040

Equity Offerings - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands				9 Months Ended
	May 11, 2015	Feb. 11, 2015	Jun. 17, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Equity [Line Items]
Common stock offered	5,175,000		8,881,794	70,716,128		59,211,859
Common stock offer price	$ 66.50		$ 44.00	$ 0.01		$ 0.01
Underwriting discount amount	$ 12,000		$ 15,600
Additional offering-related costs	600		800
Net proceeds from sale of shares	$ 331,500		$ 374,400	$ 331,360	$ 374,431
CRC Health Group, Inc [Member]
Equity [Line Items]
Total consideration related to acquisition		$ 1,300,000
Shares issued for acquisition		5,975,326

Equity-Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized common stock	4,700,000		4,700,000
Equity incentive plan available for future grant	1,885,312		1,885,312
Annual increments in employee grants			25.00%
Stock options, contractual term			10 years
Equity-based compensation expense	$ 5,327	$ 2,805	$ 14,576	$ 6,975
Unrecognized compensation expense related to unvested options			$ 53,000
Vesting period			1 year 6 months
Tax realized from stock options exercised	1,700	300	$ 8,000	3,800
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred income tax benefit	$ 2,200	$ 1,100	$ 6,000	$ 2,800

Equity-Based Compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options outstanding, Beginning balance	737,422	798,809
Options granted	199,500	226,663
Options exercised	(204,867)	(210,199)
Options cancelled	(24,500)	(77,851)
Options outstanding, Ending balance	707,555	737,422	798,809
Options outstanding, Weighted Average Exercise Price, Beginning balance	$ 32.19	$ 21.93
Options exercisable, Ending balance	96,580	91,947
Options granted, Weighted Average Exercise Price	$ 63.07	$ 49.80
Options exercised, Weighted Average Exercise Price	44.65	14.93
Options cancelled, Weighted Average Exercise Price	45.91	27.85
Options outstanding, Weighted Average Exercise Price, Ending balance	$ 42.45	$ 32.19	$ 21.93
Options outstanding, Aggregate Intrinsic Value, Beginning balance	$ 14,512	$ 10,700
Options exercisable, Weighted Average Exercise Price, Ending balance	$ 39.27	$ 28.87
Options granted, Aggregate Intrinsic Value	$ 1,681	$ 209
Options granted, Weighted Average Remaining Contractual Term	9 years 5 months 12 days	9 years 3 months
Options exercised, Aggregate Intrinsic Value	$ 9,554	$ 4,994
Options outstanding, Weighted Average Remaining Contractual Term	7 years 10 months 28 days	8 years 1 month 2 days	8 years 2 months 12 days
Options cancelled, Aggregate Intrinsic Value	$ 0	$ 0
Options exercisable, Weighted Average Remaining Contractual Term, Ending balance	6 years 1 month 6 days	6 years 3 months 18 days
Options outstanding, Aggregate Intrinsic Value, Ending balance	$ 21,093	$ 14,512	$ 10,700
Options exercisable, Aggregate Intrinsic Value, Ending balance	$ 4,466	$ 3,326

Equity-Based Compensation - Restricted Stock Activity (Detail) - Restricted Stock Award [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	722,028	461,697
Granted, Number of Shares	493,052	468,484
Cancelled, Number of Shares	(33,850)	(75,369)
Vested, Number of Shares	(214,234)	(132,784)
Unvested, Number of Shares/Units, Ending balance	966,996	722,028
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 39.77	$ 24.96
Granted, Weighted Average Grant-Date Fair Value	62.67	48.99
Cancelled, Weighted Average Grant-Date Fair Value	49.15	36.36
Vested, Weighted Average Grant-Date Fair Value	36.37	22.81
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 51.89	$ 39.77

Equity-Based Compensation - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	125,113	95,751
Granted, Number of Units	217,994	108,449
Cancelled, Number of Units	0	0
Vested, Number of Units	(125,023)	(79,087)
Unvested, Number of Shares/Units, Ending balance	218,084	125,113
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 38.73	$ 23.05
Granted, Weighted Average Grant-Date Fair Value	61.77	50.75
Cancelled, Weighted Average Grant-Date Fair Value	0	0
Vested, Weighted Average Grant-Date Fair Value	32.38	21.81
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 56.97	$ 38.73

Equity-Based Compensation - Schedule of Stock Options Valuation Assumptions (Detail) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average grant-date fair value of options	$ 21.79	$ 17.14
Risk-free interest rate	1.53%	1.70%
Expected volatility	35.00%	36.00%
Expected life (in years)	5 years 6 months	5 years 6 months

Income Taxes - Additional Information (Detail)	3 Months Ended		9 Months Ended
Income Taxes - Additional Information (Detail)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Effective tax rates	30.40%	23.20%	31.00%	33.30%

Derivatives - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Jul. 01, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
(Losses) gains associated with changes in fair value of the foreign currency forward contracts	$ 1.0	$ 1.5	$ 1.9	$ 15.3
Settlement of foreign currency forward contracts					$ 15.3

Fair Value Measurements - Carrying Amounts and Fair Values of Long-Term Debt and Contingent Consideration Liability (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration liabilities	$ 2,000	$ 3,000
Fair Value [Member] \| Amended and Restated Senior Credit Facility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amended and Restated Senior Credit Facility	999,892	525,576
Fair Value [Member] \| 12.875% Senior Notes Due 2018 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	9,738	109,688
Fair Value [Member] \| 6.125% Senior Notes Due 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	156,000	153,000
Fair Value [Member] \| 5.125% Senior Notes due 2022 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	295,500	295,500
Fair Value [Member] \| 5.625% Senior Notes Due 2023 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	654,632
Fair Value [Member] \| 9.0% and 9.5% Revenue Bonds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
9.0% and 9.5% Revenue Bonds	23,945	24,274
Carrying Amounts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration liabilities	2,000	3,000
Carrying Amounts [Member] \| Amended and Restated Senior Credit Facility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amended and Restated Senior Credit Facility	999,892	525,576
Carrying Amounts [Member] \| 12.875% Senior Notes Due 2018 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	9,101	96,420
Carrying Amounts [Member] \| 6.125% Senior Notes Due 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	150,000	150,000
Carrying Amounts [Member] \| 5.125% Senior Notes due 2022 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	300,000	300,000
Carrying Amounts [Member] \| 5.625% Senior Notes Due 2023 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	651,375
Carrying Amounts [Member] \| 9.0% and 9.5% Revenue Bonds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
9.0% and 9.5% Revenue Bonds	$ 23,945	$ 24,274

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Disclosures Regarding Financial Instruments [Line Items]
Contingent consideration, Paid		$ 5,000
Park Royal [Member]
Disclosures Regarding Financial Instruments [Line Items]
Increase (Decrease) in fair value of contingent consideration liability	$ 500
Contingent consideration, Paid			$ 5,000
Contingent consideration liabilities			$ 7,000
12.875% Senior Notes Due 2018 [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	12.875%
6.125% Senior Notes Due 2021 [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	6.125%
5.125% Senior Notes due 2022 [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	5.125%
5.625 % Senior Notes Due 2021 [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	5.625%
9.0% Revenue Bonds [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	9.00%
9.5% Revenue Bonds [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	9.50%

Segment Information - Additional Information (Detail)	9 Months Ended
Segment Information - Additional Information (Detail)	Sep. 30, 2015 Beds State Facilities
Segment Reporting Information [Line Items]
Number of facilities \| Facilities	233
Number of beds \| Beds	9,600
Number of operating states \| State	37
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities \| Facilities	181
Number of beds \| Beds	7,500
Number of operating states \| State	37
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities \| Facilities	52
Number of beds \| Beds	2,100

Segment Information - Summary of Financial Information by Operating Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Revenue	$ 479,730	$ 294,479	$ 1,299,173	$ 709,700
Segment EBITDA	108,468	65,066	292,983	149,062
Equity-based compensation expense	(5,327)	(2,805)	(14,576)	(6,975)
Debt extinguishment costs	(9,979)		(9,979)
(Loss) gain on foreign currency derivatives	(1,018)	1,527	(1,926)	15,262
Transaction-related expenses	(5,842)	(6,239)	(31,415)	(10,834)
Interest expense, net	(27,737)	(14,068)	(77,932)	(33,505)
Depreciation and amortization	(16,890)	(10,325)	(44,920)	(21,696)
Income from continuing operations before income taxes	41,675	33,156	112,235	91,314
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Revenue	379,857	217,427	1,037,250	630,825
Segment EBITDA	101,636	53,814	280,342	154,377
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Revenue	97,875	76,026	256,117	76,026
Segment EBITDA	23,015	20,253	62,197	20,253
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Revenue	1,998	1,026	5,806	2,849
Segment EBITDA	$ (16,183)	$ (9,001)	$ (49,556)	$ (25,568)

Segment Information - Summary of Financial Information by Operating Segment, Goodwill (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2015 USD ($)
Goodwill:
Beginning balance	$ 802,986
Increase from 2015 acquisitions	1,204,542
Foreign currency translation	736
Purchase price allocation and other	(27,124)
Ending balance	1,981,140
U.S. Facilities [Member]
Goodwill:
Beginning balance	693,945
Increase from 2015 acquisitions	1,114,683
Purchase price allocation and other	281
Ending balance	1,808,909
U.K. Facilities [Member]
Goodwill:
Beginning balance	109,041
Increase from 2015 acquisitions	89,859
Foreign currency translation	736
Purchase price allocation and other	(27,405)
Ending balance	$ 172,231

Segment Information - Summary of Financial Information by Operating Segment, Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Assets
Assets	$ 4,145,239	$ 2,223,590
U.S. Facilities [Member]
Assets
Assets	2,848,415	1,327,563
U.K. Facilities [Member]
Assets
Assets	1,032,804	726,693
Corporate and Other [Member]
Assets
Assets	$ 264,020	$ 169,334

Segment Information - Summary of Financial Information by Operating Segment, Assets (Parenthetical) (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 1,624,166	$ 1,069,700
U.S. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	759,200	478,100
U.K. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	820,700	578,600
Corporate and Other [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 44,300	$ 13,000

Subsequent Events - Additional Information (Detail) $ in Millions	Nov. 01, 2015 USD ($) Beds State Center	Oct. 01, 2015 USD ($) Beds	Sep. 30, 2015 State
Subsequent Event [Line Items]
Number of operating states \| State			37
Meadow View [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Number of beds \| Beds		28
Business acquisition cash paid		$ 6.9
Discovery House Group Inc [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Business acquisition cash paid	$ 118.5
Number of operating states \| State	4
Number of facilities acquired \| Center	19
Duffys Napa Valley Rehab [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Number of beds \| Beds	61
Business acquisition cash paid	$ 29.6
Cleveland House [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Number of beds \| Beds	32
Business acquisition cash paid	$ 10.2

Financial Information for the Company and Its Subsidiaries - Additional Information (Detail)	Sep. 30, 2015	Sep. 21, 2015	Feb. 11, 2015	Dec. 31, 2014	Jul. 01, 2014	Mar. 12, 2013	Nov. 01, 2011
12.875% Senior Notes Due 2018 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	12.875%	12.875%		12.875%		12.875%	12.875%
6.125% Senior Notes Due 2021 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.125%			6.125%		6.125%
5.125% Senior Notes due 2022 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.125%			5.125%	5.125%
5.625% Senior Notes Due 2023 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.625%	5.625%	5.625%	5.625%

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Balance Sheets (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 50,762	$ 94,040	$ 42,179	$ 4,569
Accounts receivable, net	214,883	118,378
Deferred tax assets	37,291	20,155
Other current assets	75,335	41,570
Total current assets	378,271	274,143
Property and equipment, net	1,624,166	1,069,700
Goodwill	1,981,140	802,986
Intangible assets, net	58,976	21,636
Deferred tax assets - noncurrent	33,278	13,141
Other assets	69,408	41,984
Total assets	4,145,239	2,223,590
Current liabilities:
Current portion of long-term debt	41,996	26,965
Accounts payable	78,384	48,696
Accrued salaries and benefits	87,110	59,317
Other accrued liabilities	56,962	30,956
Total current liabilities	264,452	165,934
Long-term debt	2,092,317	1,069,305
Deferred tax liabilities - noncurrent	22,210	63,880
Other liabilities	87,008	43,506
Total liabilities	2,465,987	1,342,625
Redeemable noncontrolling interests	8,700
Total equity	1,670,552	880,965
Total liabilities and equity	4,145,239	2,223,590
Consolidating Adjustments [Member]
Current assets:
Cash and cash equivalents				(1,925)
Deferred tax assets - noncurrent		(5,666)
Investment in subsidiaries	(1,256,878)	(1,759,337)
Other assets	(423,607)	(181,774)
Total assets	(1,680,485)	(1,946,777)
Current liabilities:
Long-term debt	(423,607)	(181,774)
Deferred tax liabilities - noncurrent		(5,666)
Total liabilities	(423,607)	(187,440)
Total equity	(1,256,878)	(1,759,337)
Total liabilities and equity	(1,680,485)	(1,946,777)
Parent [Member]
Current assets:
Deferred tax assets - noncurrent	4,621	4,563
Investment in subsidiaries	1,256,878	1,759,337
Other assets	462,205	202,708
Total assets	1,723,704	1,966,608
Current liabilities:
Current portion of long-term debt	41,781	26,750
Other accrued liabilities	11,371	13,647
Total current liabilities	53,152	40,397
Long-term debt		1,045,246
Total liabilities	53,152	1,085,643
Total equity	1,670,552	880,965
Total liabilities and equity	1,723,704	1,966,608
Combined Subsidiary Guarantors [Member]
Current assets:
Cash and cash equivalents	46,865	76,685	10,421
Accounts receivable, net	182,815	100,797
Deferred tax assets	35,471	18,395
Other current assets	66,930	36,049
Total current assets	332,081	231,926
Property and equipment, net	731,670	451,943
Goodwill	1,702,375	596,611
Intangible assets, net	56,411	19,057
Deferred tax assets - noncurrent	18,484
Other assets	28,488	18,727
Total assets	2,869,509	1,318,264
Current liabilities:
Accounts payable	64,748	39,486
Accrued salaries and benefits	72,979	47,597
Other accrued liabilities	19,592	7,688
Total current liabilities	157,319	94,771
Long-term debt	2,068,588
Deferred tax liabilities - noncurrent		21,027
Other liabilities	77,687	33,321
Total liabilities	2,303,594	149,119
Total equity	565,915	1,169,145
Total liabilities and equity	2,869,509	1,318,264
Combined Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	3,897	17,355	$ 31,758	$ 6,494
Accounts receivable, net	32,068	17,581
Deferred tax assets	1,820	1,760
Other current assets	8,405	5,521
Total current assets	46,190	42,217
Property and equipment, net	892,496	617,757
Goodwill	278,765	206,375
Intangible assets, net	2,565	2,579
Deferred tax assets - noncurrent	10,173	14,244
Other assets	2,322	2,323
Total assets	1,232,511	885,495
Current liabilities:
Current portion of long-term debt	215	215
Accounts payable	13,636	9,210
Accrued salaries and benefits	14,131	11,720
Other accrued liabilities	25,999	9,621
Total current liabilities	53,981	30,766
Long-term debt	447,336	205,833
Deferred tax liabilities - noncurrent	22,210	48,519
Other liabilities	9,321	10,185
Total liabilities	532,848	295,303
Redeemable noncontrolling interests	8,700
Total equity	690,963	590,192
Total liabilities and equity	$ 1,232,511	$ 885,495

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts	$ 488,746	$ 303,001	$ 1,324,702	$ 729,784
Provision for doubtful accounts	(9,016)	(8,522)	(25,529)	(20,084)
Revenue	479,730	294,479	1,299,173	709,700
Salaries, wages and benefits	258,410	168,632	707,583	408,680
Professional fees	30,759	14,878	83,215	36,151
Supplies	21,634	14,062	58,430	34,722
Rents and leases	8,542	3,214	22,639	8,872
Other operating expenses	57,244	31,432	148,899	79,188
Depreciation and amortization	16,890	10,325	44,920	21,696
Interest expense, net	27,737	14,068	77,932	33,505
Debt extinguishment costs	9,979		9,979
Loss (gain) on foreign currency derivatives	1,018	(1,527)	1,926	(15,262)
Transaction-related expenses	5,842	6,239	31,415	10,834
Total expenses	438,055	261,323	1,186,938	618,386
(Loss) income from continuing operations before income taxes	41,675	33,156	112,235	91,314
(Benefit from) provision for income taxes	12,669	7,703	34,794	30,383
Income (loss) from continuing operations	29,006	25,453	77,441	60,931
Income (loss) from discontinued operations, net of income taxes	80	(51)	83	(20)
Net income (loss)	29,086	25,402	77,524	60,911
Net loss attributable to noncontrolling interests	464		464
Net income attributable to Acadia Healthcare Company, Inc.	29,550	25,402	77,988	60,911
Other comprehensive income:
Foreign currency translation gain	(32,707)	(36,857)	(15,923)	(36,857)
Other comprehensive income	(32,707)	(36,857)	(15,923)	(36,857)
Comprehensive (loss) income attributable to Acadia Healthcare Company. Inc.	(3,157)	(11,455)	62,065	24,054
Consolidating Adjustments [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in earnings of subsidiaries	(50,840)	(28,607)	(127,108)	(69,446)
Income (loss) from continuing operations	(50,840)	(28,607)	(127,108)	(69,446)
Net income (loss)	(50,840)	(28,607)	(127,108)	(69,446)
Net income attributable to Acadia Healthcare Company, Inc.	(50,840)		(127,108)
Other comprehensive income:
Comprehensive (loss) income attributable to Acadia Healthcare Company. Inc.	(50,840)	(28,607)	(127,108)	(69,446)
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Salaries, wages and benefits	5,327	2,805	14,576	6,975
Interest expense, net	15,934	4,096	46,988	22,409
Debt extinguishment costs	9,979		9,979
Loss (gain) on foreign currency derivatives	1,018	(1,527)	1,926	(15,262)
Total expenses	32,258	5,374	73,469	14,122
(Loss) income from continuing operations before income taxes	(32,258)	(5,374)	(73,469)	(14,122)
Equity in earnings of subsidiaries	50,840	28,607	127,108	69,446
(Benefit from) provision for income taxes	(10,504)	(2,169)	(23,885)	(5,587)
Income (loss) from continuing operations	29,086	25,402	77,524	60,911
Net income (loss)	29,086	25,402	77,524	60,911
Net income attributable to Acadia Healthcare Company, Inc.	29,086		77,524
Other comprehensive income:
Comprehensive (loss) income attributable to Acadia Healthcare Company. Inc.	29,086	25,402	77,524	60,911
Combined Subsidiary Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts	377,582	212,376	1,029,198	612,801
Provision for doubtful accounts	(8,531)	(7,444)	(23,516)	(17,908)
Revenue	369,051	204,932	1,005,682	594,893
Salaries, wages and benefits	191,032	117,261	530,221	342,890
Professional fees	21,551	9,816	60,615	28,760
Supplies	17,349	10,784	47,287	30,137
Rents and leases	7,624	2,419	20,143	7,527
Other operating expenses	47,113	18,979	122,505	62,579
Depreciation and amortization	10,578	5,874	29,840	16,540
Interest expense, net	6,036	6,439	17,639	6,439
Transaction-related expenses	2,831	5,428	24,193	10,023
Total expenses	304,114	177,000	852,443	504,895
(Loss) income from continuing operations before income taxes	64,937	27,932	153,239	89,998
(Benefit from) provision for income taxes	21,383	12,517	50,634	36,766
Income (loss) from continuing operations	43,554	15,415	102,605	53,232
Income (loss) from discontinued operations, net of income taxes	80	(51)	83	(20)
Net income (loss)	43,634	15,364	102,688	53,212
Net income attributable to Acadia Healthcare Company, Inc.	43,634		102,688
Other comprehensive income:
Comprehensive (loss) income attributable to Acadia Healthcare Company. Inc.	43,634	15,364	102,688	53,212
Combined Non-Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts	111,164	90,625	295,504	116,983
Provision for doubtful accounts	(485)	(1,078)	(2,013)	(2,176)
Revenue	110,679	89,547	293,491	114,807
Salaries, wages and benefits	62,051	48,566	162,786	58,815
Professional fees	9,208	5,062	22,600	7,391
Supplies	4,285	3,278	11,143	4,585
Rents and leases	918	795	2,496	1,345
Other operating expenses	10,131	12,453	26,394	16,609
Depreciation and amortization	6,312	4,451	15,080	5,156
Interest expense, net	5,767	3,533	13,305	4,657
Transaction-related expenses	3,011	811	7,222	811
Total expenses	101,683	78,949	261,026	99,369
(Loss) income from continuing operations before income taxes	8,996	10,598	32,465	15,438
(Benefit from) provision for income taxes	1,790	(2,645)	8,045	(796)
Income (loss) from continuing operations	7,206	13,243	24,420	16,234
Net income (loss)	7,206	13,243	24,420	16,234
Net loss attributable to noncontrolling interests	464		464
Net income attributable to Acadia Healthcare Company, Inc.	7,670		24,884
Other comprehensive income:
Foreign currency translation gain	(32,707)	(36,857)	(15,923)	(36,857)
Other comprehensive income	(32,707)	(36,857)	(15,923)	(36,857)
Comprehensive (loss) income attributable to Acadia Healthcare Company. Inc.	$ (25,037)	$ (23,614)	$ 8,961	$ (20,623)

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Thousands			3 Months Ended		9 Months Ended		12 Months Ended
	May 11, 2015	Jun. 17, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Operating activities:
Net income (loss)			$ 29,086	$ 25,402	$ 77,524	$ 60,911
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization			16,890	10,325	44,920	21,696
Amortization of debt issuance costs					5,017	2,229
Equity-based compensation expense			5,327	2,805	14,576	6,975
Deferred income tax (benefit) expense					28,925	4,645
(Income) loss from discontinued operations, net of taxes			(80)	51	(83)	20
Debt extinguishment costs			9,979		9,979
Loss (gain) on foreign currency derivatives			1,018	(1,527)	1,926	(15,262)
Other					1,122	163
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net					(28,905)	(25,395)
Other current assets					(12,201)	1,322
Other assets					(4,879)	(2,086)
Accounts payable and other accrued liabilities					(8,316)	1,078
Accrued salaries and benefits					8,888	8,972
Other liabilities					5,071	3,805
Net cash (used in) provided by continuing operating activities					143,564	69,073
Net cash provided by (used in) discontinued operating activities					(1,479)	(27)
Net cash (used in) provided by operating activities					142,085	69,046
Investing activities:
Cash paid for acquisitions, net of cash acquired					(391,216)	(722,797)
Cash paid for capital expenditures					(200,841)	(70,680)
Cash paid for real estate acquisitions					(21,976)	(22,247)
Settlement of foreign currency derivatives					(1,926)	15,262
Other					(887)	(733)
Net cash used in investing activities					(616,846)	(801,195)
Financing activities:
Borrowings on long-term debt					1,150,000	307,500
Borrowings on revolving credit facility					310,000	230,500
Principal payments on revolving credit facility					(310,000)	(120,000)
Principal payments on long-term debt					(23,813)	(5,625)
Repayment of assumed CRC debt					(904,467)
Repayments of senior notes					(88,331)
Payment of debt issuance costs					(25,584)	(10,909)
Payment of premium on senior notes					(6,890)
Issuance of common stock, net	$ 331,500	$ 374,400			331,360	374,431
Common stock withheld for minimum statutory taxes, net					(7,582)	(3,477)
Excess tax benefit from equity awards					8,020	3,779
Other					(374)
Cash paid for contingent consideration						(5,000)
Net cash provided by (used in) financing activities					432,339	771,199
Effect of exchange rate changes on cash					(856)	(1,440)
Net (decrease) increase in cash and cash equivalents					(43,278)	37,610
Cash and cash equivalents at beginning of the period					94,040	4,569	$ 4,569
Cash and cash equivalents at end of the period			50,762	42,179	50,762	42,179	94,040
Consolidating Adjustments [Member]
Operating activities:
Net income (loss)			(50,840)	(28,607)	(127,108)	(69,446)
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries			50,840	28,607	127,108	69,446
Change in operating assets and liabilities, net of effect of acquisitions:
Other assets					300	(165)
Net cash (used in) provided by continuing operating activities					300	(165)
Net cash (used in) provided by operating activities					300	(165)
Financing activities:
Principal payments on long-term debt					300	165
Cash provided by (used in) intercompany activity					(600)	1,925
Net cash provided by (used in) financing activities					(300)	2,090
Net (decrease) increase in cash and cash equivalents						1,925
Cash and cash equivalents at beginning of the period						(1,925)	(1,925)
Parent [Member]
Operating activities:
Net income (loss)			29,086	25,402	77,524	60,911
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries			(50,840)	(28,607)	(127,108)	(69,446)
Amortization of debt issuance costs					5,347	1,891
Equity-based compensation expense					14,576	6,975
Deferred income tax (benefit) expense					(58)	(754)
Debt extinguishment costs			9,979		9,979
Loss (gain) on foreign currency derivatives			1,018	(1,527)	1,926	(15,262)
Change in operating assets and liabilities, net of effect of acquisitions:
Other assets					(300)	165
Net cash (used in) provided by continuing operating activities					(18,114)	(15,520)
Net cash (used in) provided by operating activities					(18,114)	(15,520)
Investing activities:
Settlement of foreign currency derivatives						15,262
Net cash used in investing activities						15,262
Financing activities:
Borrowings on long-term debt					1,150,000	307,500
Borrowings on revolving credit facility					310,000	230,500
Principal payments on revolving credit facility					(310,000)	(120,000)
Principal payments on long-term debt					(23,813)	(5,625)
Repayment of assumed CRC debt					(904,467)
Repayments of senior notes					(88,331)
Payment of debt issuance costs					(25,584)	(10,909)
Payment of premium on senior notes					(6,890)
Issuance of common stock, net						374,431
Common stock withheld for minimum statutory taxes, net					(7,582)	(3,477)
Excess tax benefit from equity awards					8,020	3,779
Cash provided by (used in) intercompany activity					(83,239)	(775,941)
Net cash provided by (used in) financing activities					18,114	258
Combined Subsidiary Guarantors [Member]
Operating activities:
Net income (loss)			43,634	15,364	102,688	53,212
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization			10,578	5,874	29,840	16,540
Deferred income tax (benefit) expense					27,035	3,218
(Income) loss from discontinued operations, net of taxes			(80)	51	(83)	20
Other					1,088	134
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net					(16,535)	(23,347)
Other current assets					(14,287)	1,067
Other assets					(4,881)	(2,086)
Accounts payable and other accrued liabilities					(10,510)	(2,752)
Accrued salaries and benefits					7,953	6,546
Other liabilities					5,821	3,549
Net cash (used in) provided by continuing operating activities					128,129	56,101
Net cash provided by (used in) discontinued operating activities					(1,479)	(27)
Net cash (used in) provided by operating activities					126,650	56,074
Investing activities:
Cash paid for acquisitions, net of cash acquired					(88,308)	(722,797)
Cash paid for capital expenditures					(116,466)	(60,223)
Cash paid for real estate acquisitions					(21,976)	(22,247)
Settlement of foreign currency derivatives					(1,926)
Other					(887)	(733)
Net cash used in investing activities					(229,563)	(806,000)
Financing activities:
Issuance of common stock, net					331,360
Other					(374)
Cash paid for contingent consideration						(5,000)
Cash provided by (used in) intercompany activity					(257,037)	765,347
Net cash provided by (used in) financing activities					73,949	760,347
Effect of exchange rate changes on cash					(856)
Net (decrease) increase in cash and cash equivalents					(29,820)	10,421
Cash and cash equivalents at beginning of the period					76,685
Cash and cash equivalents at end of the period			46,865	10,421	46,865	10,421	76,685
Combined Non-Guarantors [Member]
Operating activities:
Net income (loss)			7,206	13,243	24,420	16,234
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization			6,312	4,451	15,080	5,156
Amortization of debt issuance costs					(330)	338
Deferred income tax (benefit) expense					1,948	2,181
Other					34	29
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net					(12,370)	(2,048)
Other current assets					2,086	255
Other assets					2
Accounts payable and other accrued liabilities					2,194	3,830
Accrued salaries and benefits					935	2,456
Other liabilities					(750)	256
Net cash (used in) provided by continuing operating activities					33,249	28,657
Net cash (used in) provided by operating activities					33,249	28,657
Investing activities:
Cash paid for acquisitions, net of cash acquired					(302,908)
Cash paid for capital expenditures					(84,375)	(10,457)
Net cash used in investing activities					(387,283)	(10,457)
Financing activities:
Principal payments on long-term debt					(300)	(165)
Cash provided by (used in) intercompany activity					340,876	8,669
Net cash provided by (used in) financing activities					340,576	8,504
Effect of exchange rate changes on cash						(1,440)
Net (decrease) increase in cash and cash equivalents					(13,458)	25,264
Cash and cash equivalents at beginning of the period					17,355	6,494	6,494
Cash and cash equivalents at end of the period			$ 3,897	$ 31,758	$ 3,897	$ 31,758	$ 17,355